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During HIV-1 entry, CD4 and a coreceptor (either CCR5 or CXCR4) must interact with the envelope
glycoprotein (Env). The coreceptor N-terminus and extracellular loops are critical domains that interact
cooperatively with Env to drive the release of gp41 for fusion with the host membrane. Conformational
changes in Env that follow coreceptor engagement to trigger fusion are poorly understood. We explored the
individual contribution of interactions between an HIV-1 Env and the coreceptor N-terminus with a variant,
termed CEMAX, that mediated fusion and infection using a coreceptor construct that expressed only the first
27 residues of the CXCR4 N-terminus, fused to a CD4 anchoring molecule (X4-NT/CD4). CEMAX
acquired mutations in gp41, but also contained a severely truncated V3 loop in gp120. Here we describe the
derivation and characterization of HIV-1s with full V3 loops and combinations of these gp41 changes that
enabled efficient utilization of an R5-NT/CD4 construct containing the first 19 residues of CCR5 fused to a
CD4 anchoring molecule. The determinants for this gain of function were mapped to gp41 mutations in: the
fusion peptide, an N-terminal helical domain, and heptad repeat-2. We demonstrated that these changes in
heterologous HIV-1s conferred the same phenotype. We also evaluated the mechanism of this novel “N-
terminus only” usage of CCR5. Although global changes in trimer architecture were not detected by several
antibodies, the acquisition of N-terminus only usage was associated with reduced sensitivity to a gp41 fusion
inhibitor, consistent with more rapid fusion kinetics. Our findings also indicated that infection of cells
expressing CD4 and R5-NT/CD4 was markedly enhanced in the absence of Vpu and in the presence of
tetherin, likely as a result of tetherin-mediated formation of cell-associated viral aggregates and facilitation of
cell-to-cell spread. Based on new structural insights of the CD4-activated trimer in its final conformational
state before coreceptor engagement, this novel phenotype is consistent with a model in which gp41 mutations
destabilize interactions between the gp41 N-terminus and a CD4-induced pocket formed near the trimer
core, lowering the threshold for triggering and enabling the coreceptor N-terminus to become sufficient for
gp41 release and cell fusion.
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ABSTRACT 
 
INSIGHTS INTO HIV-1 CORECEPTOR ENGAGEMENT AND ITS CONTRIBUTION TO 
MEMBRANE FUSION 
Kritika E. Kumar 
James A. Hoxie 
 
During HIV-1 entry, CD4 and a coreceptor (either CCR5 or CXCR4) must interact with 
the envelope glycoprotein (Env). The coreceptor N-terminus and extracellular loops are 
critical domains that interact cooperatively with Env to drive the release of gp41 for 
fusion with the host membrane. Conformational changes in Env that follow coreceptor 
engagement to trigger fusion are poorly understood. We explored the individual 
contribution of interactions between an HIV-1 Env and the coreceptor N-terminus with a 
variant, termed CEMAX, that mediated fusion and infection using a coreceptor construct 
that expressed only the first 27 residues of the CXCR4 N-terminus, fused to a CD4 
anchoring molecule (X4-NT/CD4). CEMAX acquired mutations in gp41, but also 
contained a severely truncated V3 loop in gp120. Here we describe the derivation and 
characterization of HIV-1s with full V3 loops and combinations of these gp41 changes 
that enabled efficient utilization of an R5-NT/CD4 construct containing the first 19 
residues of CCR5 fused to a CD4 anchoring molecule. The determinants for this gain of 
function were mapped to gp41 mutations in: the fusion peptide, an N-terminal helical 
domain, and heptad repeat-2. We demonstrated that these changes in heterologous 
HIV-1s conferred the same phenotype. We also evaluated the mechanism of this novel 
“N-terminus only” usage of CCR5. Although global changes in trimer architecture were 
not detected by several antibodies, the acquisition of N-terminus only usage was 
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associated with reduced sensitivity to a gp41 fusion inhibitor, consistent with more rapid 
fusion kinetics. Our findings also indicated that infection of cells expressing CD4 and R5-
NT/CD4 was markedly enhanced in the absence of Vpu and in the presence of tetherin, 
likely as a result of tetherin-mediated formation of cell-associated viral aggregates and 
facilitation of cell-to-cell spread. Based on new structural insights of the CD4-activated 
trimer in its final conformational state before coreceptor engagement, this novel 
phenotype is consistent with a model in which gp41 mutations destabilize interactions 
between the gp41 N-terminus and a CD4-induced pocket formed near the trimer core, 
lowering the threshold for triggering and enabling the coreceptor N-terminus to become 
sufficient for gp41 release and cell fusion.  
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CHAPTER 1 
 
 
GENERAL INTRODUCTION 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2 
OVERVIEW OF HIV PATHOGENESIS 
Human Immunodeficiency Virus type 1 (HIV-1) is the etiological agent of Acquired 
Immunodeficiency Syndrome (AIDS) and is a significant global health issue. In 2014, 
approximately 37 million people were living with the disease, and roughly 2 million new 
cases were recorded [251]. HIV-1 transmission rates are generally low, ranging from 
0.1% to 10% per exposure event [24, 181]. In most cases, infection is established by a 
single transmitter/founder (T/F) variant from a diverse swarm, resulting in a profound 
genetic bottleneck. The frequency of the establishment of a single versus multiple 
variant infection may differ by route, reflecting varying selection pressures that T/F 
viruses likely face [213]. CD4+ T cells, particularly memory T cells that express high 
levels of CCR5, represent the initial targets for mucosal transmission by the viral 
envelope glycoprotein (Env) [30, 63, 217]. A burst of viral replication contributes to early 
and massive depletion of CD4+ T cells in gut associated lymphoid tissue (GALT) in 
primary or acute infection [121]. It has been proposed that the consequent damage of 
the intestinal lining permits translocation of microbial products into the blood. This could 
help to enhance the general immune activation that is a hallmark of HIV disease [130].  
 
Approximately 3-6 weeks after infection, specific anti-viral responses from the humoral 
and cellular immune systems can be detected, including a precipitous drop in viremia to 
a viral setpoint and a transient stabilization of CD4+ T cells. Following the induction of 
the immune response, there is a relatively long period of time where individuals display 
few or no clinical symptoms. Throughout this clinical latent phase, there is usually a 
decline of CD4+ cells accompanied by chronic viral replication (clinical latency does not 
imply viral latency) despite high antibody responses [47, 170, 173]. Selective pressure 
from neutralizing antibodies and cytotoxic T lymphocytes are contributing forces to viral 
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evolution. The rate at which mutants accumulate in the population is a consequence of 
the error rate of viral replication and viral fitness. Substitutions, deletions, insertions, and 
duplications, especially in env, contribute to genetic diversity, but recombination between 
variants can also play a role [45–47]. 
 
The apparent steady state of the chronic phase gradually breaks down after months to 
years, and evidence suggests that a high viral load and chronic immune activation are 
responsible for the progression to AIDS [153]. Patients are highly susceptible to 
opportunistic infections and neoplasms at this stage. A change in viral tropism from 
CCR5+ to CXCR4+ CD4+ cells due to mutations in env is associated with a more rapid 
decline in CD4+ cells in peripheral blood and an accelerated progression to AIDS [49, 
115, 190, 211]. It is not known if CXCR4-tropic viruses are a cause or consequence of 
advanced disease [158].  
 
Current therapies that use a combination of antiretroviral drugs suppress viral loads and 
prevent the outgrowth of resistant mutants. Moreover, several preclinical studies have 
provided some amount of protection against HIV by targeting infection at the level of 
entry [3, 54, 58, 74, 94, 154]. Therefore, understanding the early events of infection, 
particularly HIV entry, not only holds significance for the prevention of transmission and 
pathogenesis, but also the potential for therapeutics development against various target 
sites on Env. 
 
FUNDAMENTALS OF HIV ENTRY 
HIV entry involves a series of interactions between host receptors and the viral 
glycoprotein, envelope (Env) (Figure 1-1). The precursor of this type I integral 
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membrane protein (gp160) is proteolytically processed into the surface subunit (gp120) 
and transmembrane subunit (gp41), which are non-covalently linked. Each Env exists as 
a heavily glycosylated trimer of heterodimers consisting of the gp120 and gp41 subunits. 
The gp120 subunit is responsible for receptor binding and contains five inner domain 
conserved regions (C1-C5) and five surface-exposed genetically variable loops (V1-V5). 
With the exception of V5, each variable loop is formed via a disulfide bond at its base 
and all loops are highly glycosylated [100, 180]. This glycan shield acts as a viral 
defense mechanism against the antibody response [138, 150]. Some loops also assist 
the virus in immune evasion [123, 160], while the third variable loop (V3) of gp120 plays 
a key role in determining which coreceptor is used [84, 96, 104]. V3 is sequestered 
beneath V1 and V2 and behind the N197 glycan on the adjacent gp120 protomer [13, 
112, 143]. The gp41 subunit contains the class I fusion machinery and is made up of a 
long cytoplasmic tail, a membrane spanning domain, and an ectodomain. The 
ectodomain consists of three main domains: the hydrophobic N-terminal fusion peptide 
(FP) and heptad repeat-1 and -2 (HR1 and HR2) [31, 186].  Gp41 is initially protected by 
regions of Env that prevent spontaneous triggering and keep the trimer in a closed pre-
fusion conformation [168, 169].  
 
From its basal state, gp120 undergoes profound rearrangements following each 
subsequent recognition event. Env first interacts with attachment factors, a rate-limiting 
step that is not necessarily essential or always specific, but does regulate the efficiency 
of the process (at least in in vitro systems). Heparin sulfate proteoglycan, α4β7 integrin, 
and C-type lectins, such as DC-SIGN, increase the proximity between Env and host 
receptors [10, 43, 86, 132, 203, 232, 233]. Incorporation of intracellular adhesion 
molecule-1 (ICAM-1) into virions is also known to markedly enhance infection of target 
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cells expressing its ligand LFA-1, or lymphocyte function- associated antigen-1 [124]. 
The next step of viral entry is strictly required and involves binding of Env gp120 to its 
primary receptor, CD4 [144, 151] (Figure 1-1). This host glycoprotein is part of the 
immunoglobulin superfamily and is found on the surface of T helper cells, monocytes, 
macrophages, and dendritic cells [23, 135]. The intermolecular contact between Env and 
the first domain (D1) of CD4 occurs in a conserved pocket in gp120 (CD4bs), and results 
in several interactions between residues, including the formation of hydrogen bonds and 
a salt bridge between Arg59 of CD4 and the aspartic acid residue at position 368 of 
gp120 [128]. Binding of CD4 causes substantial conformational changes in gp120 and 
gp41 subunits [128] that are influenced by the “intrinsic reactivity” of Env, or the 
propensity to transition to a lower energy state [92, 162].  Haim et al. describes this 
property for CD4-independent infection; in this case, there is an increased likelihood that 
Env can overcome the activation energy barrier without CD4 and move down a steep 
energy gradient [92] (Figure 1-2). Emerging insights from cryo-electron microscopy 
structures of CD4-induced intermediates reveal a series of coordinated allosteric 
changes that propagate across gp120 that include the rigid body movement of gp120 
subunits rotating away from the trimer and the formation of the bridging sheet (BS) within 
gp120 [167]. This BS minidomain is composed of two pairs of anti-parallel β-strands 
from the inner and outer domains of gp120 [191, 192]. The redirection of V1/V2 exposes 
the coreceptor binding site and V3 loop, positioning these domains to face the host 
membrane. These conformational changes are communicated to gp41, where the gp120 
C1 region (residues 63-72) packs against the top of the HR1 helix from a neighboring 
protomer, instead of against the HR1 from the same protomer in the pre-fusion state. 
This prevents “hair-triggering” of gp41 and further progression toward a more stable 
fusogenic state [167].  
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Together, the base of the V3 and the BS form the coreceptor binding site. Following CD4 
engagement, the coreceptor binding site along with distal portions of V3 must interact 
with a chemokine receptor, typically CCR5 (R5) or CXCR4 (X4) [5, 17, 41, 56, 62, 66, 
82] (Figure 1-1). Both coreceptors are seven-transmembrane G-protein-coupled 
receptors (GPCRs) that contain an extracellular N-terminal domain with three 
extracellular loops (ECLs) connected to three intracellular loops by transmembrane 
segments (Figure 1-3). The first and second ECLs contain cysteines that form a 
disulfide bond. The beginning of the CCR5 N-terminus consists of 19 amino acids 
(CXCR4 contains 27 residues), followed by a cysteine that forms a disulfide bond with 
another cysteine in ECL3 [11, 16, 18, 21, 28, 33, 60, 61, 134, 174, 179, 185, 196, 198, 
226, 244]. Binding of cognate chemokine ligands (MIP-1α, MIP-1β, and RANTES for 
CCR5 and SDF-1 for CXCR4) results in a G-protein-mediated cascade of intracellular 
signaling events that regulate trafficking and effector responses [44, 89, 187].  
 
Two principle interactions must occur between gp120 and a coreceptor: the crown of V3 
engages the extracellular loops (particularly ECL2), while the BS and base of V3 engage 
the tyrosine-sulfated N-terminus [20, 40, 42, 50, 61, 67, 76, 80] (Figure 1-1, insets). R5 
viruses exhibit more varied use of the CCR5 ECL and N-terminus regions [40, 42, 50, 
77, 80, 99, 114] with sulfated tyrosines on the N-terminus playing an essential role, as 
demonstrated in structures of the CCR5 N-terminus and of a sulfated functional antibody 
in complex with gp120 and CD4 [42, 80, 81]. Of the four sulfated tyrosines of the CCR5 
N-terminus, Y10 and Y14 play a critical role in interacting with the BS [78, 80, 81, 99]. 
Truncation of the CCR5 N-terminus generally results in the loss of function as a 
coreceptor, but can be restored in trans with tyrosine-sulfated N-terminal peptide mimics 
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[79]. The V3 loop-ECL2 interaction plays a prominent role for X4 viruses, with a smaller 
contribution from the bridging sheet/N-terminus (BS/NT) interaction [77]. The three 
sulfated tyrosines (Y7, Y12, Y21) in the CXCR4 N-terminus are not as critical. The V3 
loop likely interacts with residues located in a lipophilic pocket of the coreceptor [34, 61, 
96, 100, 166]. Envs that use CXCR4 have positively charged residues in their V3s 
(usually at positions 11, 24, and 25) that are thought to interact with key negatively 
charged residues in ECL2 [106, 111, 215, 216]. Structurally, the V3 loop is contains a 
beta-hairpin GPG(R/Q) tip that is conserved in both R5 and X4 viruses [100]. The length 
of the V3 is largely conserved with a majority of sequences containing between 30 and 
35 amino acids [129]. Exclusive use of the V3/ECL interaction (particularly ECL1) has 
been demonstrated for one lab-derived R5-tropic isolate using an engineered coreceptor 
lacking an N-terminus, where determinants were mapped to V3, V1/V2, and a V4 glycan 
[152, 176–178]. Within the past few years, Env variants with truncated V3 loops have 
been generated to study the determinants for V3 usage, and as a consequence 
developed greater dependence on the BS/N-terminus interaction and resistance to small 
molecule antagonists that target coreceptor ECLs [14, 15, 129, 139, 165, 166, 183].  
 
After coreceptor binding, additional conformational changes occur that trigger the 
release of gp41. These structural changes are poorly understood, and the mechanism 
by which gp120 communicates to gp41 to initiate membrane fusion is also unclear. This 
final step of entry emphasizes how Env is energetically primed for a series of tightly 
orchestrated conformational changes. Structural and biochemical studies of influenza 
hemagglutinin and HIV-1 Env have led to a common model for the fusion process 
(reviewed in [71, 243]). This fusion mechanism involves the insertion of the previously 
occluded gp41 FP into the host membrane (Figure 1-1). This creates a transient 
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conformational species consisting of a homotrimeric molecular tether referred to as the 
pre-hairpin intermediate. The HR1 and HR2 segments of each strand then fold on one 
another in an anti-parallel manner, and in the context of the trimer, collapse to form a 
thermodynamically stable trimer-of-hairpins or 6-helix bundle (6HB) [37, 237, 238, 243]. 
All viruses studied [243] form a final trimer-of-hairpins irrespective of whether the fusion 
subunit has a central α-helical coiled-coil (Class I protein), whether it is composed of a β-
structure (Class II protein) or whether it displays a combination of both structures (Class 
III protein). The transition to forming the 6HB is critical for the juxtaposition of the virus 
and cell before membrane mixing. While many accept the evidence that HIV fusion 
occurs at the plasma membrane in a pH-independent manner, one study showed 
dynamin-dependent fusion within endocytic compartments [156]. Irrespective of where 
fusion occurs, the mechanism of entry is likely the same, and results in the delivery of 
the viral contents in to the host cytoplasm.   
 
KEY STRUCTURAL INSIGHTS INTO ENVELOPE 
Our understanding of the molecular architecture of Env has been largely advanced 
through 3D structure determination. Perhaps the greatest challenges for the field are that 
1) Env readily dissociates into subunits and 2) transmembrane proteins are notoriously 
difficult to crystallize in their native conformations, making classical biophysical methods 
difficult to use. Moreover, although neutralizing epitopes and targets for inhibitors can be 
elucidated through recent efforts using electron microscopy (EM) and x-ray 
crystallization, these technologies still only provide snapshots of entry. However, 
previous observations of HIV-1 entry can be studied in a more appropriate context by 
using these recently solved structures of the Env trimer. 
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Strategies to studying envelope structure 
There have been critical advances in the field of structural biology that have 
revolutionized our understanding of the Env trimer. The first structure of the inner core of 
monomeric HIV-1 gp120 bound to sCD4 and the CD4i monoclonal antibody 17b was 
determined more than a decade ago [245]. Early electron tomography studies of Env at 
the virion surface provided a rough framework of the trimer [247, 249, 250]. Efforts to 
obtain molecular models used crystal structures that were fitted to these low-resolution 
reconstructions yielding further details [95, 140]. However, because crystallographic 
studies required the removal of flexible variable loops [128] and glycans [125], many 
early structures presented an incomplete view of the surface of Env [234]. However, EM 
can be conducted in the presence of complex glycans and establishes a complementary 
technique to x-ray studies.  
 
One interesting approach to achieving a soluble stable version of the trimer was to 
engineer 1) a disulfide bond (SOS) between gp120 and gp41 and 2) an isoleucine to 
proline (IP) HR1 mutation [19, 202]. Further modifications of this “SOSIP” trimer were 
created, including truncating gp41 at position 664 before the membrane proximal 
external region (MPER) [118, 120] and using a clade A HIV-1, termed BG505 [201]. 
Negative-stain EM of BG505.664 SOSIP showed compact homogeneous trimers that 
also retained antigenic properties of native Env [118, 201]. Moreover, comparisons 
between tomographic reconstructions and single-particle EM revealed striking 
similarities [22, 140]. Using these proteins to map epitopes of broadly neutralizing 
antibodies (bnAbs) has been highly successful [13, 22, 57, 75, 112, 136, 143, 169]. 
SOSIPs react with newly discovered bNAbs that recognize only cleaved, native trimers 
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and interact with both subunits [22, 75], providing a strong argument that the structures 
of these trimers reflect those found on the surface of virions.  
 
The HIV fusion machinery 
The structure of post-fusion gp41 in its 6HB form was solved approximately 20 years 
ago, with HR1 helical segments at the center of the bundle and HR2 segments lying 
within grooves of the HR1 core [238]. In the recently described pre-fusion trimer, HR1 
segments form a coiled coil in the center of the trimer perpendicular to the membrane 
(Figure 1-4) [169]. HR2 helices stretch diagonally from the membrane at the periphery. 
The N- and C-terminal regions of each gp120 run through the core of each gp41. A 
membrane-proximal collar composed of four gp41 helices (α-6 through α-9) completes a 
single circle around the extended gp120 termini, holding the trimer in place. A 
methionine (Met530, proximal to the fusion peptide) is inserted into a triple tryptophan 
clasp (Trp623, Trp628, and Trp631 from α-8 and α-9 helices) that is likely disrupted 
upon coreceptor binding to release the gp120 termini [169]. The pre-fusion conformation 
of SOSIP FP is initially oriented away from the trimer core and partially disordered [127, 
137, 167, 169, 220]. It is likely that the FP can transition between a conformation that is 
exposed to one that is sequestered based on the ability of the trimer to undergo dynamic 
structural changes, or “breathing” between different open and closed conformations. 
Based upon exciting new advances in the structural biology field, a new cryoEM 
reconstruction has revealed novel insights into the global rearrangements that propagate 
throughout the trimer upon CD4 binding [167]. Specifically, the N- and C-termini of 
gp120, along with trimeric HR1, move away from the core, while the fusion peptide 
proximal region (FPPR) and N-terminus of HR1 (HR1N) forms a stable helix. The FP 
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undergoes a large conformational rearrangement and is embedded in a newly formed 
hydrophobic pocket near the trimer core. An extensive network of interactions between 
gp120 and gp41 residues, particularly in HR1, likely contributes to the stability of the pre-
fusion state and the CD4-bound intermediate. The gp41 tryptophan clasp is retained 
even after CD4 binding, further contributing to the preservation of this intermediate state 
without prematurely releasing the buried FP [167]. The profound rearrangements that 
must occur within gp41 and gp120 to release the FP for fusion upon coreceptor binding 
are still poorly understood and remain challenging to study.   
 
Several new antibodies that bind to the gp120/gp41 interface have recently emerged 
[75, 101]. For example, the bnAb PGT151 was used in EM studies with full length Env 
and revealed the FP as a new site of vulnerability [22, 75]. Newer bnAbs, such as 
VRC34 and ACS202, also implicate the FP as a target [126]. In the PGT151 or VRC34 
bound states of Env, the FP projects away from the trimer core, but is fully ordered due 
to interaction with the bnAbs [126, 136]. Much of what is described about Env has been 
determined using bnAbs as molecular chaperones to solve structures, uncovering new 
epitopes and driving new efforts toward a vaccine.  
 
HIV ENTRY INHIBITORS 
Uncovering the mechanism of early events of HIV-1 infection has directly benefited our 
ability to develop therapeutics. Since both Env and host receptors are involved in entry, 
they serve as attractive targets. Moreover, these specific reagents can also be used as 
tools to understand the entry pathway and highlight Env’s molecular plasticity. Currently, 
there are two FDA-approved entry inhibitors, enfuvirtide (Fuzeon) and maraviroc 
(Selzentry). Recombinant soluble CD4 (sCD4) was also created to act as a molecular 
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decoy during infection. Studies using sCD4 showed promising signs of neutralizing HIV-
1 in vitro [83, 103, 218, 230], however clinical and manufacturing applications proved to 
be challenging [52, 207]. This section will mainly serve as a review of those inhibitors 
that block coreceptor engagement and fusion, and highlight how they can be utilized to 
study HIV-1 entry and kinetics.  
 
Coreceptor inhibitors 
Understanding the architectural basis for chemokine receptors and mapping the binding 
sites for their cognate chemokines and small molecule inhibitors gives us a deeper 
understanding for these complex proteins. In the “two-site model” for chemokine binding, 
the CCR5 N-terminus and ECLs interact with the chemokine core (Site 1/chemokine 
recognition site). The activation site (Site 2) located in the transmembrane regions, 
interacts with the flexible N-terminus of the chemokine [69]. Maraviroc is a small 
molecule that has been characterized as an antagonist. It occupies the bottom of a deep 
hydrophobic pocket that is defined by residues from all CCR5 transmembrane helices 
with the exception of helix IV [226] (Figure 1-5). This pocket may overlap with Site 2, but 
is distinct from the chemokine and HIV-1 gp120 binding sites (Site 1), which implies that 
maraviroc blocks through a noncompetitive and allosteric mechanism of action. 
Importantly, maraviroc binding locks CCR5 in an inactive conformation that is no longer 
recognized by its cognate chemokines or HIV-1 gp120, thereby preventing downstream 
conformational changes from being relayed to the cytoplasmic domain and G-protein 
[226]. Compared to the structure of CXCR4 bound to the IT1t small molecule antagonist, 
the binding site for maraviroc is much deeper and occupies a larger area of the cavity 
[226]. Other small molecules, like aplaviroc [131], vicriviroc [224], and TAK-779 [68], also 
function as allosteric inhibitors.  
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CCR5 antagonists are an unusual class of therapeutics in that they target the host rather 
than the virus. Nevertheless, as with other HIV treatments, drug resistance can occur 
and typically with accompanying mutations in V3 [159]. The outgrowth of pre-existing 
X4-using HIV-1 strains that were present at very low levels is a common mechanism of 
resistance in vivo, but is rare in vitro [239]. Additionally, adaptive changes in Env can 
contribute to competitive resistance where HIV increases its affinity for low levels of 
unbound CCR5. Increasing the concentration of inhibitor overcomes competitive 
resistance by HIV [184]. Noncompetitive resistance facilitates recognition of unbound 
and drug-bound conformations of CCR5. Here a plateau effect may occur if entry 
through drug-bound CCR5 is less efficient than with free receptor, and 100% inhibition 
never occurs [184, 240]. Another documented method of resistance occurs with 
increased dependence on the BS/NT interaction [14, 15, 129, 139, 165, 166, 183]. The 
differential recognition of inhibitor-bound CCR5 (or the more common route to treatment 
failure involving the expansion of pre-existing X4-using viruses in vivo that are not 
sensitive to these inhibitors) and the genetic signatures that lead to various pathways of 
resistance and escape will influence the administration of small molecules inhibitors in 
clinical settings. 
 
Fusion inhibitors 
Gp41 fusion inhibitors are designed to prevent the formation of the irreversible 6HB 
structure (Figure 1-6). After receptor engagement, the N-terminal coiled coil of gp41 
becomes transiently exposed and vulnerable to fusion inhibitors. Enfuvirtide (or T20) 
was designed to mimic the HR2 region of gp41 and targets HR1, resulting in the 
prevention of 6HB formation [35, 119]. In addition to other drawbacks, resistance 
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typically occurs in the region to which T20 binds, specifically in the N-terminal GIV motif 
[51]. As a result, newer generations of “C-peptide” mimics, such as C37, were generated 
with increased potency and longer half-lives. The inclusion of the highly conserved 
pocket-binding domain is also an important feature of some of these newer inhibitors 
[35, 36, 195]. 
 
In contrast to the N-terminus, the C-terminal region of the gp41 ectodomain is partially 
exposed to antiviral inhibitors even before receptor-mediated conformational changes 
occur [194]. Although the sequence of the HR2 region is somewhat variable across HIV-
1 strains, the specific amino acids that make contact with the gp41 N-terminal coiled-coil 
are highly conserved [93, 195]. The 5-Helix polypeptide inhibitor was designed to take 
advantage of these features of gp41 and acts as a molecular mimic of the 6HB structure, 
containing all HR domains except one HR2 segment that normally resides on the 
periphery of the core. This vacancy is a high-affinity binding site for the HR2 region of 
the gp41 ectodomain, ultimately preventing the formation of the 6HB [195]. Compared to 
some antibodies that exhibit a narrower range of reactivity, 5-Helix is active against a 
wide variety of lab-adapted and primary isolates [194]. 
 
DISSEMINATION OF HIV BY INFECTED CD4+ CELLS 
The previous three sections gave a detailed overview of the first step in the HIV-1 life 
cycle: entry. The next section describes how an infected cell subsequently transmits the 
virus to target cells, and the evolution of a late-acting host restriction factor that can 
modulate viral spread at the assembly stage of the viral life cycle.  
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Cell-to-cell transmission of HIV 
HIV-1 can infect cells via two distinct routes, either through a cell-free pathway or by 
being transmitted by direct cell-to-cell contact. Cell-to-cell spread is more efficient and is 
the predominant mode of transmission in lymphoid tissue [39, 161]. There are 
advantages associated with cell-to-cell spread that could be exploited by viruses, 
particularly if they are not fit enough for cell-free transmission. Evidence shows that 
when the cell-free pathway is experimentally blocked at certain stages, transmission 
becomes reliant on cell-cell spread [248].  
 
Cell-to-cell spread takes place at the virological synapse (VS) between an infected cell 
and an uninfected target cell. The VS multi-molecular structure forms at the surface of T 
cells, involving interactions between Env and host receptors (CD4 and CCR5 or CXCR4) 
[39, 102, 109, 199, 204]. Cytoskeletal remodeling of the actin and tubulin network 
ultimately directs assembly and egress of HIV-1 towards the target cell [109, 110]. 
Virions bud into the synaptic cleft and mediate fusion at the plasma membrane or 
through endocytosis [25, 102].  
 
Vpu versus tetherin 
One important mechanism that cells have evolved to resist viral infection is a group of 
interferon-inducible innate restriction factors. APOBEC3G, TRIM5α, SAMHD1, and 
tetherin, among others, have all been proposed to inhibit lentiviruses in certain contexts. 
Tetherin, however, is a late-acting host restriction factor in contrast to the other proteins.  
 
Tetherin (BST-2) is a small Type II membrane protein with two membrane anchors that 
physically traps and tethers mature virions at the plasma membrane, inhibiting viral 
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release from cells [53, 172]. Lentiviruses have evolved three proteins to independently 
target tetherin, highlighting the importance of controlling its function across species. 
Tetherin is antagonized by HIV-1 Vpu, while HIV-2 employs Env, and SIV uses Nef. The 
16-kDa accessory protein Vpu [163, 164, 223] antagonizes tetherin by targeting it for 
proteosomal or lysosomal degradation [53, 64, 87, 105, 148, 155, 221]. Vpu can also 
target newly synthesized CD4 for degradation [146] and inhibits NFκB activation [27]. 
There is evidence that Vpu-deficient HIV-1 can overcome tetherin-mediated restriction in 
the context of cell-to-cell transmission [90, 107, 175, 206, 229]. Jolly et al. showed that 
tetherin is enriched at the VS and enhances VS-mediated cell-to-cell transfer of Vpu-
deficient virus [108]. Early work on Vpu suggested that although Vpu-defective virus 
production was inhibited in T cell lines, viral spread in the culture was not [122, 209, 
222]. Additionally, in vitro selection for HIV-1 variants that utilize cell-to-cell spreading 
infection results in mutations in Vpu [90]. Collectively, tetherin could be considered as a 
modulator of transmission, rather than just a host restriction factor, and Vpu could 
provide advantages and disadvantages to HIV-1 depending on the cellular context [48, 
228]. Chapter four explores an in vitro setting in which the absence of the HIV-1, Vpu, 
promotes cell-to-cell spread that is mediated by tetherin. The modulation between cell-
free and cell-to-cell spreading infection is intriguing, given the existence of in vivo 
environments where cell-to-cell transfer serves as an important mode of dissemination 
[39, 161]. Moreover, cell-to-cell spread can enable HIV-1 to rapidly evade the antibody 
response [1, 205], though the identification of a subset of broadly neutralizing antibodies 
was shown to inhibit both cell-free and cell-mediated infection of primary CD4+ T-cells 
[147].  
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THESIS GOALS 
Efforts to develop therapeutics to target HIV can be improved by understanding the 
molecular mechanisms behind coreceptor engagement by Env. There are several gaps 
of knowledge concerning the structural rearrangements that must occur after gp120 
interacts with CCR5 or CXCR4. Moreover, the gp120 signals that are subsequently 
communicated to gp41 to drive fusion remain poorly understood. Env interacts with 
coreceptor in two distinct ways: 1) the base of the V3 and BS with the N-terminus and 2) 
distal portions of V3 with ECL2. We know that viruses can differ in their ability to interact 
with coreceptors, with some displaying increased dependence on the ECLs [152, 176–
178], while others are more reliant on the N-terminus [14, 15, 129, 139, 165, 166, 183]. 
Given this, we developed a novel model to study the BS/NT interaction in isolation 
(termed “N-terminus only” usage) by creating chimeric coreceptors that express a 
portion of the CCR5 or CXCR4 N-terminus fused to a CD4-based anchoring protein. 
Envs that can mediate fusion or infection using these novel constructs are termed “N-
terminus only” Envs. We previously adapted a variant of the HIV-1 R3A virus to mediate 
highly efficient use of the X4-NT/CD4 chimeric coreceptor. This mutant virus contained a 
severely truncated V3, which was predicted to increase dependence on the BS/NT 
interaction. However, certain gp41 mutations that were acquired during adaptation were 
hypothesized to ultimately confer this novel gain of function. Two questions were 
addressed in Chapter 2. First, could an N-terminus only using virus with an intact V3 be 
derived in vitro? Second, are these key gp41 mutations necessary and sufficient to 
mediate N-terminus only usage for an Env with an intact V3? In Chapter 3, the 
mechanistic basis and antigenic consequences of this phenotype were characterized. In 
Chapter 4, the roles of Vpu and tetherin were explored in the context of in vitro 
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replication of N-terminus only viruses. A model is proposed in which tetherin enhances 
infection by mediating cell-to-cell spread of Vpu-deficient N-terminus only viruses.  
 
Native HIV undergoes thermodynamic changes upon CD4 binding. We hypothesize that 
an activation energy barrier also exists for coreceptor binding that follows the higher 
energy barrier described for CD4 binding [92] (Figure 1-2). Because CD4-independent 
HIV-1s are hypothesized to make the transition to lower energy states in the absence of 
CD4, we suggest that N-terminus only Envs can more easily negotiate movement over a 
smaller activation energy barrier for coreceptor binding. The mechanism for this 
phenotype is explained by structures that form upon CD4 binding that are poised, but not 
sufficient to trigger the release of the gp41 FP. Mutations in gp41 act to disrupt inter- and 
intra-protomeric constraints at a sub-threshold level of triggering, such that a minimal 
interaction with the CCR5 N-terminus is sufficient for further conformational 
rearrangements to the final fusogenic form.  
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FIGURES 
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Figure 1-2: Model of potential energy gradient for HIV-1 entry. Gp41 with pre-hairpin 
intermediate and 6-helix bundle shown at the right of graph. Arrows indicate hypothetical 
activation energy barriers for receptor binding.  
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Figure 1-4: Pre-fusion structure of HIV-1. Select secondary structures are labeled and 
the location of the trimer axis is indicated with an arrow. Gp41 (rainbow from blue to 
orange) forms a 4-helix collar that wraps around the gp120 N- and C-termini (red). The 
Met530 side chain is inserted into a triple tryptophan clasp (inset). Adapted from 
Pancera M., et al. Nature, 2014 (514). 
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Figure 1-5: CCR5 and CXCR4 HIV-1 coreceptor structures with small molecule 
antagonists. Maraviroc binds in a deep yet open pocket of CCR5 (purple) formed by the 
transmembrane helices, and occupies a larger area compared to the CXCR4/IT1t 
structure (green). Adapted from Tan Q., et al. Science, 2013 (341). 
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Figure 1-6: Schematic of gp41 fusion inhibitors that target heptad repeats. The 
ectodomain of gp41 is depicted, including the fusion peptide (FP) and heptad repeat-1 
(HR1) and -2 (HR2). HR2 is shown in orange along with the corresponding C37 linear 
peptide mimic (sequence shows C37 residues 625 to 661 of HIV-1HXB2 gp41 in orange). 
HR1 is shown in blue with the 5-Helix polypeptide.   
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CHAPTER 2 
 
 
DERIVATION OF AN HIV-1 CAPABLE OF USING THE CCR5 AMINO TERMINUS IN 
THE ABSENCE OF EXTRACELLULAR LOOPS AND IDENTIFICATION OF ITS 
GENETIC DETERMINANTS 
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ABSTRACT 
Interactions of the HIV-1 envelope (Env) with coreceptors (CoR) CCR5 or CXCR4 
involve interactions of 1) the distal V3 loop with CoR extracellular loops (ECLs), and 2) 
the gp120 bridging sheet and base of V3 with the CoR N-terminus.  We described a lab-
adapted variant of the dual-tropic, Clade B isolate R3A, termed CEMAX, containing a 
partial deletion of V3, that can mediate fusion and infection using a CoR construct that 
lacks ECLs and expresses only the first 27 amino acids of the X4 N-terminus (X4-
NT/CD4). Remarkably, the appearance of three mutations in the gp41 fusion peptide 
(FP) (A512V, F519I, G524V) and a single mutation in HR2 (I646L) correlated with the 
acquisition of this phenotype. We sought to determine if this phenotype could be 
conferred to a virus containing a full length V3 to enable analyses of underlying 
structure/function and mechanistic determinants to be performed. Remarkably, in cell-
cell fusion assays, the FP changes that were acquired in CEMAX collectively conferred 
to the parental R3A Env a partial ability to mediate CD4-dependent fusion using a 
chimeric construct containing the first 19 residues of the CCR5 N-terminus fused to the 
same CD4-based anchoring molecule as the X4-NT/CD4. To determine if these changes 
were sufficient to confer infectivity in the context of a replication competent virus, we 
introduced two or four of these changes into parental R3A virus containing a full V3 loop, 
and both viruses were able to be adapted to infect cells expressing CD4 and CCR5 N-
terminus construct. One adapted virus, Dbl cl-1, acquired a mutation at the N-terminal 
residue of gp41 (A512V) that was already present in Quad cl-4 before adaptation. Both 
clones maintained the mutations that were introduced in the FP and gained a mutation in 
a region flanking the start of HR1 (A541T). Viruses containing the three FP mutations 
plus the A541T mutation were able to confer CD4-dependent fusion and infectivity on 
CD4 T cell lines expressing the CCR5 N-terminus construct, although the kinetics of 
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infection were markedly enhanced by the inclusion of the HR2 mutation. Based on 
recent structural insights of the HIV-1 trimer, we hypothesize that A541T and the FP 
mutations destabilize packing of the FP within the trimer, reducing the triggering 
threshold for its release following CoR engagement.  
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INTRODUCTION 
HIV entry involves a series of cooperative interactions between the viral envelope 
glycoprotein (Env) and cellular proteins. During this process distinct functions are 
performed by heterotrimers of gp120 and gp41 subunits. Entry is initiated by binding of 
gp120 to CD4, which occurs in a highly conserved and recessed pocket on gp120 [128]. 
The resulting conformational changes form and expose a gp120 binding site for 
chemokine receptors CCR5 (R5) or CXCR4 (X4) [5, 41, 56, 62, 66, 82, 171]. Viral 
tropism is determined primarily by the V3 loop on gp120, although additional domains 
can also contribute [96]. Following chemokine receptor engagement, additional 
conformational changes lead to the release of gp41 and formation of the fusion 
intermediate that is likely extended with its amino terminal fusion peptide (FP) anchored 
in the target cell membrane [85]. Thereafter, gp41 heptad repeat-1 (HR1) and -2 (HR2) 
reorganize in the context of a trimer to form the 6-helix bundle (6HB), providing energy 
required to bring viral and cell membranes together, and initiating lipid mixing that drives 
membrane fusion in the final stage of entry [37, 38, 141, 238, 243]. Although the major 
domains involved in coreceptor engagement have been identified, conformational 
changes that occur following coreceptor binding and lead to the release of gp41 are 
poorly understood.  
 
The interaction of CD4-bound gp120 with CCR5 or CXCR4 involves two principal 
components: 1) the distal portion of the V3 loop binding to a pocket formed by the 
coreceptor’s extracellular loops (ECLs); and 2) the bridging sheet (BS), composed of 
four anti-parallel beta strands from the base of the V1/V2 loop and the C4 domain, along 
with the base of V3, binding to the coreceptor N-terminus [29, 98–100, 185, 191, 192, 
225, 226, 244]. Sulfated tyrosines on the CCR5 N-terminus play a critical role in binding 
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to pockets on the bridging sheet for R5 viruses [99], while these modified residues, 
although present, are not required for X4 viruses [77].  Structural and mutagenesis 
studies have shown differences in how CCR5 and CXCR4 are used by R5 and X4 
viruses, respectively [65]. The V3 interaction with ECLs, mainly ECL2, is particularly 
important for X4 viruses with a weaker contribution from the V3/X4 N-terminus 
interaction [29, 61, 142, 171].  In contrast, R5 viruses exhibit a more variable use of the 
CCR5 ECLs and N-terminus [40, 42, 50, 77, 80, 99, 114], with sulfated tyrosines on the 
N-terminus playing an essential role [42, 80].  
 
Interestingly, lab-adapted variants of HIV-1 have demonstrated that the V3/ECL and the 
BS/N-terminus interactions of Env with coreceptors can be dissociated. Kabat showed 
that R5-tropic JRCSF could be adapted to replicate on a cell line expressing CCR5 
engineered to lack the first 18 residues of the N-terminal domain [152, 178]. Viral 
determinants for this phenotype were mapped to residues on gp120 and shown to confer 
more rapid fusion kinetics following CCR5 binding, that were hypothesized to lower the 
triggering threshold for release of gp41 [152, 177, 178]. Additionally, HIV-1s with 
truncated V3 loops have been derived that exhibit a corresponding increase in 
dependence on the BS/N-terminus interaction [4, 129, 139, 165, 166, 183]. These V3-
truncated viruses exhibited complete resistance to small molecule antagonists of 
coreceptors that bind to a hydrophobic pocket formed by their membrane spanning 
domains [68, 116, 117, 212, 231, 236]. We previously reported an HIV-1 variant, termed 
CEMAX, derived from the dual-tropic HIV-1 isolate R3A containing an 18 amino acid 
deletion of its distal V3 loop that could be adapted to mediate CD4-dependent entry on a 
construct containing only the first 27 amino acids of the CXCR4 N-terminus and lacking 
all ECLs [2]. This “N-terminus only” virus proved to be highly useful in identifying small 
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molecule inhibitors of the BS/N-terminus interaction. Although CEMAX represented a 
proof-of-concept that the coreceptor N-terminus in the absence of ECLs could be 
sufficient for entry, the determinants that permitted this phenotype and the underlying 
mechanisms are unknown. In addition, the observation that this minimal coreceptor 
interaction became sufficient for entry raised the possibility that triggering threshold for 
release of gp41 had been altered as a result of structural changes in Env.  
 
We hypothesized that CEMAX and its novel “N-terminus only” phenotype created an 
opportunity to study the structure/function relationships in the Env trimer that were 
associated with release of gp41 following coreceptor engagement. However, because 
CEMAX contained a severely truncated V3 that has the potential to disrupt inter- and 
intra-protomeric interactions within the Env trimer we sought to determine if this 
phenotype could be acquired by an HIV-1 with a full length V3 loop. As will be described, 
using parental R3A containing an intact V3, we derived a variant that was adapted for 
CD4-dependent entry, fusion and replication on a construct containing only the first 19 
amino acids of the CCR5 N-terminus and lacking all ECLs. Remarkably, we showed that 
changes required for this phenotype were localized to gp41 (three in the FP, one in HR2, 
and one in an alpha-helical collar implicated in restraining the release of gp120 [169]. 
We extended these findings by showing that these changes, when engineered into other 
HIV-1 variants could confer this same phenotype of N-terminus only fusion and infection. 
Coupled with an emerging understanding of the structure of the HIV-1 Env trimer, our 
findings suggest that these gp41 mutations destabilize the packing of the gp41 FP within 
the Env trimer, lowering the threshold for coreceptor induced release of gp41, and 
accelerating fusion kinetics. 
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MATERIALS AND METHODS 
Chimeric coreceptors. The chimeric X4-NT/CD4 and R5-NT/CD4 coreceptors 
were created using overlapping PCR. The first 27 amino acids of CXCR4 (or 19 amino 
acids of CCR5) were fused to the distal 72 residues (from Val386 to Ile458) of CD4. 
The following primers were used:  
CCR5 NT Fwd: CACCATGGATTATCAAGTGTCAAGTCC 
CCR5 NT Rev: CATCAATTATTATACATCGGAGCCC 
CXCR4 NT Fwd: ATGGAGGGGATCAGTATATACAC  
CXCR4 NT Rev: CTATGACTCCATGAAGGAACCC  
CD4 Fwd: CATCGGAGCCCGTTCTGCCCACATGGTCC  
CD4 Rev: CGGTTTCAGAAGACATGTAGCCCCATTTGA  
Cells. SupT1-derived cells were maintained in RPMI 1640 medium 
supplemented with 10% fetal bovine serum (FBS), 2 mM glutamine, and 2 mM penicillin-
streptomycin. Zinc-finger nuclease technology was used to ablate expression of X4 in 
SupT1 cells, and a clone called A66 was isolated [182]. The pENLS replication-defective 
lentiviral vector [189] was used to stably express the X4-NT/CD4 or R5-NT/CD4 proteins 
on A66 cells, creating the A66/R5NT and A66/X4NT lines, respectively. Following 
transduction, coreceptor-positive cells were single-cell cloned and tested for receptor 
expression using fluorescence-activated cell sorting (FACS) and anti-CCR5 (3A9 and 
2D7, BD Pharmingen) and anti-CXCR4 (4G10 and 12G5) antibodies. The Japanese 
quail cell line, QT6, and the human embryonic kidney cell line, 293T, were cultured in 
Dulbecco’s modified Eagle medium (DMEM) supplemented with 10% FBS, 2 mM 
glutamine, and 2 mM penicillin/streptomycin. 
Derivation of “N-terminus only” viruses, capable of mediating coreceptor-
dependent entry in the absence of ECLs. The generation of CEMAX has been 
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previously described [2]. Briefly, a replication-competent virus bearing the CEM-c11 env 
on an NL4-3 backbone was serially passaged in a 1:10 mix of A66/CXCR4 cells [183] 
and A66/X4NT cells. An Env clone termed CEMAX-c7 was isolated and capable of 
efficiently infecting A66/X4NT cells. HIV-1 R3A Envs containing either two (A512V and 
F519I) or four (A512V, F519I, G524V, and I646L) mutations in gp41, named Db-PRE 
and Quad-PRE, were subcloned in to an NL4-3 backbone. These replication-competent 
viruses were serially passaged in a 1:10 mix of A66/CCR5 and A66/R5NT cells until 
infection spread to roughly 10% of the cells, at which point virus-containing supernatants 
were serially passaged 10 times in a pure culture of A66/R5NT cells. Infection was 
monitored by immunofluorescence microscopy (IFA) using an anti-p24Gag monoclonal 
antibody (25.4; kindly provided by Jan McClure, University of Washington).  
Env cloning, plasmid construction, and mutagenesis. To isolate adapted env 
clones from infected cultures, genomic DNA was prepared using a QIAamp DNA minikit 
(Qiagen) according to the manufacturer’s instructions, and env sequences were PCR 
amplified using a Phusion High Fidelity PCR kit (NEB) and primers that flank the env 
region. PCR products were then cut with EcoRI and XhoI restriction enzymes and ligated 
to the pcDNA3.1 expression vector and the pNL4-3 HIV-1 genome construct. The 
identities of the recombinant clones were confirmed using DNA sequencing. Mutant env 
genes (R3A, YU2, and BG505.W6M.ENV.B1) in pcDNA3.1 expression vectors were 
created using a QuikChange site-directed mutagenesis kit (Stratagene) following the 
manufacturer’s protocol. The identities of the mutations were confirmed by DNA 
sequencing. Selected R3A mutant env genes were digested with EcoRI and XhoI and 
ligated to the pNL4-3 HIV-1 genome construct to generate recombinant replication-
competent viruses. Expression constructs containing CD4 and CCR5 cDNAs and the 
reporter plasmid encoding luciferase under the control of a T7 promoter have been 
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described previously [73, 197]. The R5-NT/CD4 and X4-NT/CD4 constructs were cloned 
into the pcDNA3.1 vector. 
Cell-cell fusion assays.  Cell-cell fusion assays were performed as previously 
described [73, 197]. Briefly, QT6 effector cells were infected with the recombinant 
vaccinia strain VTF1.1 that expresses T7 polymerase at a multiplicity of infection of 10 
for 1 h at 37°C. Cells were then transfected for 4 h with the appropriate env expression 
vector using the calcium phosphate method. Effector cells were then incubated overnight 
at 32°C in the presence of rifampin. QT6 target cells were transfected with the desired 
receptor expression vectors and a T7-luciferase reporter construct using the calcium 
phosphate method for 4 h, followed by overnight expression at 37°C. Effector cells were 
then added to target cells in the presence of 100 ug/ml rifampin and 100 nM cytosine 
arabinoside, and cell-cell fusion was assessed 7 h later by lysing cells with 0.5% Triton 
X-100-phosphate-buffered saline, adding luciferase substrate (Promega), and 
quantifying luciferase activity with a Thermo LabSystems Luminoskan Ascent 
luminometer.  
Replication-competent viral infection assays. 293T cells were transfected for 
4 h by the calcium phosphate method with pNL4-3 constructs containing env genes to 
generate infectious molecular clones. Cell supernatants were collected 48 h later and 
stored at -80°C. Viral p24 concentrations were determined by an enzyme-linked 
immunosorbent assay (Perkin-Elmer). SupT1-derived cells were inoculated with 
equivalent amounts of p24-containing virus and incubated overnight at 37°C. Cells were 
washed in RPMI medium supplemented with 5% FBS to remove residual virus, and viral 
replication was monitored over time by measuring viral reverse transcriptase (RT) 
activity in the culture supernatants. 
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RESULTS 
CEMAX, an HIV-1 with a truncated V3 loop, adapted to use the CXCR4 N-terminus 
for infection in the absence of ECLs.  We previously described an HIV-1 variant, 
termed CEMAX, derived from dual tropic isolate, R3A, that exhibited CD4-dependent 
entry and fusion using as a coreceptor a construct that contained only the first 27 amino 
acids of the CXCR4 N-terminus (up to but not including Cys-28) fused to a CD4-based 
anchoring molecule that contained the CD4 cytoplasmic tail, membrane spanning 
domain and 11 amino acids from the membrane proximal ectodomain (Figure 2-1) [2]. 
This X4-NT/CD4 construct was stably expressed in A66 cells, a derivative of the CD4+ T 
cell line SupT1 in which the endogenous CXCR4 gene had been disrupted [183], and 
surface expression documented by FACS using a monoclonal antibody specific for the 
CXCR4 N-terminus (Figure 2-2).  
 
To generate CEMAX, 18 amino acids from the distal V3 loop were first deleted (leaving 
the first and last 9 amino acids and containing a Gly-Ala-Gly linker) and this virus was 
adapted to replicate in SupT1 cells that stably expressed CCR5 [129]. This virus, termed 
TA1, which became exclusively R5 tropic, was subsequently adapted to reacquire X4-
tropism by passaging first in SupT1 [183] and then in CEM T cell lines [2] that each 
expressed CXCR4 but not CCR5. During adaptation to CEM, the V3 loop lost an 
additional 4 amino acids, retaining only the first 8 and last 6 residues, not including its N- 
and C-terminal cysteines. An Env clone from the CEM-adapted virus, designated, CEM-
c11, was used to construct a virus that could be adapted for growth in A66 cells that 
expressed the X4-NT/CD4 construct, and an Env clone, designated CEMAX-c7, was 
isolated [2]. Parental R3A and a virus containing the CEM-c11 Env replicated in A66 
cells that expressed CXCR4, but not the X4-NT/CD4 construct, whereas the virus 
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containing the CEMAX-c7 Env (CEMAX) was able to replicate on both lines (Figure 2-3, 
Table 2-1). 
 
The sequence of parental R3A and Env clones from the CEM-adapted (CEM-c11) and 
X4-NT/CD4-adapted (CEMAX-c7) viruses are shown in Figure 2-4. Remarkably, Env 
changes associated with this gain of function for using the X4 N-terminus in the absence 
of ECLs were located in gp41, including two in the fusion peptide (i.e., F519I and 
G524V), although additional mutations in gp41 had also been acquired prior to 
adaptation to CEM cells (i.e., A512V and A538T, among others) and were also 
maintained (Figure 2-4) [4, 129, 183]. These findings represented a proof of concept 
that an HIV-1 containing a truncated V3 loop, previously shown to exhibit increased 
dependence on the CCR5 N-terminus [129], could be further adapted to exhibit 
exclusive dependence on the CXCR4 N-terminus in the absence of ECLs.   
 
Adapting an HIV-1 containing an intact V3 loop to use the CCR5 N-terminus for 
fusion in the absence of ECLs. Although the novel functional properties of CEMAX 
raised the possibility that it could be used to explore structural themes in Env triggering, 
its truncated V3 loop would be expected perturb Env trimer organization, confounding an 
assessment of the structural basis for this phenotype. We therefore sought to derive an 
HIV-1 that could mediate infection on a coreceptor N-terminus in the absence of ECLs 
while maintaining a full length V3 loop. For this adaptation we created an additional 
construct containing the first 19 amino acids of the R5 N-terminus (up to but not 
including Cys-20) fused to the same CD4-based construct we used to create X4-NT/CD4 
(Figure 2-1). This R5-NT/CD4 construct was stably expressed in A66 cells, and surface 
expression was documented by FACS (Figure 2-2). Of note, despite 40 serial passages 
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of R3A in mixtures of A66 cells expressing CCR5 (A66/CCR5 cells) or R5-NT/CD4 
(A66/R5NT cells), wildtype R3A remained unable to infect A66/R5NT cells (not shown). 
 
Because CEMAX’s gain of function to utilize the CXCR4 N-terminus for fusion in the 
absence of ECLs was associated with mutations in gp41, we evaluated the possibility 
that these changes could contribute to the phenotype. The CEMAX gp41 changes in its 
fusion peptide (A512V, F519I and G524V) and in HR2 (I646L) were shown to be the 
most important when introduced individually and in combination into the parental R3A 
Env and assessed for their ability to mediate cell-cell fusion on QT6 cells expressing 
CD4 and either wildtype CCR5 or the R5-NT/CD4 construct.  We also evaluated wildtype 
CXCR4 and X4-NT/CD4 fusion, but the ability of Envs to mediate fusion with the X4 
chimeric construct was negligible (data not shown). As shown in Figure 2-5, relative to 
the CEMAX-c7 Env clone, which could mediate fusion on the R5-NT/CD4 construct at a 
level approximately 90% of its use of wildtype CCR5, when these changes were 
introduced individually into R3A, a small but reproducible increase in fusion (10-20% of 
fusion on wildtype CCR5) was seen for F519I or G524V, with little effect seen for A512V 
or I646L. When these changes were introduced in combination, F519I and G524V 
together (termed “Dbl-PRE”) or all four mutations (termed “Quad-PRE”) increased R5-
NT/CD4-dependent fusion to 30-40% of wildtype CCR5.  
 
R3A Envs containing the Dbl or Quad sets of mutations were inserted into a proviral 
backbone and viruses again passaged in mixtures of A66/CCR5 and A66/R5NT cells. 
Although Dbl- and Quad-PRE viruses were able to replicate in A66/CCR5 cells, but not 
A66/R5NT cells alone, both viruses could be adapted to use the R5-NT/CD4 construct 
after 19 or 8 passages, respectively. After these adapted viruses were passaged an 
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additional 10 times in pure A66/R5NT cells, Env clones were derived, termed Dbl cl-1 
and Quad cl-4, respectively, and each shown to confer robust replication to viruses, 
comparable to the uncloned adapted viral swarms, on A66/R5NT cells (Figure 2-6 and 
Table 2-1). 
 
Mutations in gp41 were sufficient to confer infectivity to R3A using the R5 N-
terminus in the absence of ECLs. Mutations acquired in the Dbl cl-1 and Quad cl-4 
Env clones during adaptation to A66 cells expressing R5-NT/CD4 are shown in Figure 2-
7. Although sporadic changes in gp120 were seen for both Envs, none were shared, and 
a glycan at position 187 was lost for Dbl cl-1. Both Envs acquired an A541T mutation 
proximal to HR1. This same mutation had also been seen during adaptation of V3-
truncated R3A to SupT1 cells (Figure 2-4).  In addition, changes were seen for both 
clones at the fusion peptide N-terminus at position 512 with Dbl cl-1 Env acquiring an 
A512V and Quad cl-4 Env changing its Val to an Ile. Additionally, while Quad cl-4 
maintained the G524V mutation, Dbl cl-1 changed its Val to an Ile. Dbl cl-1 also acquired 
a G640D in HR2 while Quad cl-4 maintained the I646L mutation.  
 
To determine if the acquired changes in gp41, particularly the acquisition of the A541T, 
were sufficient to confer usage of the CCR5 N-terminus in the absence of ECLs, R3A 
Envs with four (A512V, F519I, G524V, and A541T) or five mutations (A512V, F519I, 
G524V, A541T and the I646L in HR2) were made, designated 4x and 5x, respectively 
(Table 2-1). When 4x and 5x mutations were inserted into an R3A proviral backbone, 
both viruses replicated in A66 cells expressing wildtype CCR5 with kinetics and viral 
peaks that were similar to parental R3A and to a virus containing the Quad cl-4 Env 
clone (Figure 2-8A). Remarkably, both 4x and 5x viruses were also able to replicate in 
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A66 cells expressing the R5-NT/CD4 construct, although with kinetics that were slower 
than the Quad cl-4 Env-containing virus (Figure 2-8B). The implications for this 
observation will be explored in further detail in Chapter 4. No additional changes were 
noted in Env from sequencing bulk DNA after 25 days of replication. These findings 
clearly demonstrated that mutations in the R3A gp41 could confer to the parental virus, 
the ability to initiate infection using the CCR5 N-terminus in the absence of ECLs.  
 
Mutations in the gp41 N-terminus also confer N-terminus-only fusion to 
heterologous HIV-1 isolates. Given that residues in the gp41 N-terminus that conferred 
N-terminus only fusion to the R3A isolate are highly conserved, we next determined, 
using a cell-cell fusion assay, if a similar phenotype could be conferred to heterologous 
HIV-1 isolates.  R5-topic isolates YU2 (Clade B) and BG505 (Clade A) were selected for 
these studies. Each have residues at gp41 positions 512 (Ala), 519 (Phe), 524 (Gly), and 
541 (Ala) that are identical to those in R3A, although at position 646, BG505 had a Leu 
in contrast to R3A and YU2, which contained an Ile.  As with R3A, near background 
levels of fusion using the R5-NT/CD4 construct were seen for the YU2 and BG505 Envs. 
However, when all mutations were introduced to YU2 (or all but the HR2 mutation were 
added to BG505), a marked increase in fusion on the R5-NT/CD4 construct was seen 
(Figure 2-8). 
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FIGURES 
  
 
Figure 2-1. Amino-terminal chimeric coreceptors. The first 27 (green) or 19 (orange) 
residues of the CXCR4 or CCR5 N-terminus, respectively, were fused to a CD4-based 
anchor (blue), containing 11 amino acids from the membrane proximal ectodomain, 
transmembrane domain, and cytoplasmic tail.  
CXCR4 CCR5
CD4
X4-NT/CD4 R5-NT/CD4
386
1
27
M
E
G
I
S
I
Y
T
S
D
N
Y
T
E
E
M
G
S
G
D
Y
D
S
M
K
E
P
V
L
P
T
W
S
T
P
V
Q
P
M
A
L
I
V
.
.
1
19
M
D
Y
Q
V
S
S
P
I
Y
D
I
N
Y
Y
T
S
E
P
V
L
P
T
W
S
T
P
V
Q
P
M
A
L
I
V
.
.
C
C
C
C C C
C
C
386
 40
 
 
Figure 2-2. Cell surface expression of wildtype and chimeric coreceptors. (A to D) 
Control cells stably expressing CD4 and wildtype coreceptors were analyzed by flow 
cytometry. (E and F) Cells stably expressing CD4 and either the X4-NT/CD4 or R5-
NT/CD4 chimeric coreceptor were analyzed by flow cytometry after being stained with 
antibodies recognizing the CCR5 N-terminus (3A9), CXCR4 N-terminus (4G10), CCR5 
ECLs (2D7), and CXCR4 ECLs (12G5). Chimeric constructs and cells created by 
George Leslie; FACS performed by Beth Haggarty.  
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Figure 2-3. Replication of an N-terminus only variant of R3A with a severely 
truncated V3 loop. Growth curves are shown for parental R3A, CEM-c11, and the X4-
NT/CD4 adapted CEMAX clone in A66 cells alone or A66 cells expressing either CXCR4 
or X4-NT/CD4. RT activity in culture supernatants was measured at the indicated time 
points. Results from a representative experiment performed by George Leslie and 
Andrea Jordan are shown.  
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Figure 2-4. Alignment of Env sequences for R3A, TA1, ∆V3-X4, CEM-c11, and 
CEMAX-c7. Locations of gp120 variable loops (V1/V2, V3, V4, and V5) are indicated. 
Putative N-linked glycosylation sites are indicated by black circles. CEMAX-c7 acquired 
six gp41 mutations, but none in gp120 compared to CEM-c11. R3A numbering is used 
here.  
 
R3A MRVKGIRRNCQRWWKWGIMLL GILMICNAEQLWVTVYYGVPVWKEATTTLFCASDAKGHDTEAHNVWATHACVPTDPNPQEIVLENVTENFNMWKNNMVEQMHEDVISLWDQSLKPCVKL 
TA1 --------------------- ---------------------------------------------------------------------------------------------------
p7.10.7 --------------------- ---------------------------------------------------------------------------------------------------
CEM-cl1 --------------------- ---------------------------------------------------------------------------------------------------
CEMAX --------------------- ---------------------------------------------------------------------------------------------------
1        |         |         |        40         |         |         |        80         |         |         |       120
•
R3A TPLCVTLNCTDVMNNVNTTTN SSERMIEKGEIKNCSFNINTNMRNKVQKEHALFYKLDVVPIDNTTKNNYTSYRLISCNTSVITQACPKVSFEPIPIHYCAPAGFAILKCRDKKFNGTGP 
TA1 --------------------- -------------------------------------------••••----------------------------------------------------
p7.10.7 -------D-----------------V------------------------------P---------------------------R-----------------------------------
CEM-c11 -------D--------------G----K---------------------K------P--------------R------------R-----------------------------------
CEMAX -------D--------------G----K---------------------K------P--------------R------------R-----------------------------------
121        |         |         |       160         |         |         |       200         |         |         |       240
• • • • • • • •
R3A CTNVSTVQCTHGIRPVVSTQL LFNGSLAEEDVVIRSANFSDNAKTILVQLNETVVMNCTRPGNNTRKRVTLGPGRVYYTTGQIIGDIRKAHCNLSRAGWNNTLERIAIKLREQFQNKTIA 
TA1 -------------K-----------------------------------------------------••••GVG••••••••-------------------A------------------
p7.10.7 --------------------- -----------I-------------------------------A--••••GVG••••••••-----------------S---------------S-I—-
CEM-c11 --------------------- -----------I-------------------------------A-•••••••••••••••••••--------------S-----------------I--
CEMAX --------------------- -----------I-------------------------------A-•••••••••••••••••••--------------S-----------------I--
241        |         |         |       280         |         |         |       320         |         |         |       360
• • • • • • • • •
R3A FNQSSGGDPEITTISFNCGGE FFYCNSTQLFNGTWNGTWLDVKQGNGTITLPCRIKQIINLWQEVGKAMYAPPISGQIRCSSNITGLLLTRDGGTSNETTTTETFRPGGGNMKDNWRSEL
TA1 --------------------- ---------------------------------------------------------------------------------------------------
p7.10.7 --------------------- ----------------A---------I--------------------------R-------------------------N-------------------
CEM-c11 --------------------- ----------------A---------I---------------------H----R-------------------------N-------------------
CEMAX --------------------- ----------------A---------I---------------------H----R-------------------------N-------------------
361        |         |         |       400         |         |         |       440         |         |         |       480
• • • • • • •
R3A YRYKVIKIEPLGVAPTKARRR VVQREKRAVGIGAVFLGFLGAAGSTMGAASMTLTVQARQLLSGIVQQQNNLLRAIEAQQQLLKLTVWGIKQLQARVLAVERYLKDQQLLGIWGCSGKLI 
TA1 --------------------- -------V-------------------------------------------------------------------------------------------
p7.10.7 --------------------- -------V----------------------------T--------------------------------------------------------------
CEM-c11 --------------------- -------V----------------------------T--------------------------------------------------------------
CEMAX --------------------- -------V------I----V----------------T--------------------------------------------------------------
481        |         |         |       520         |         |         |       560         |         |         |       600
R3A CTTNVPWNTSWSNKSMHQIWD NMTWMQWEREIDNYTGLIYSLIEESQNQQEKNEQELLALDEWASLWNWFDITKWLWYIKIFIMIVGGLIGLRIVFTVLSIVNRVRKGYSPLSFQTRLPT 
TA1 --------------------- ---------------------------------------------------------------------------------------------------
p7.10.7 --------------------- -------------------------------------S------------------------I--------K---------------------------
CEM-c11 --------------------- -------------------------------------S------------------------I------S-K---------------------------
CEMAX --------------------- ---------------------L---------------S------------------------I------S-K-A-------------------------
601        |         |         |       640         |         |         |       680         |         |         |       720
• •• •
R3A PRGPDRPGGIEEEGGDRDRDG SGPLVNGFLAIIWVDLRSLCLFSYHRLRDLLLIVARIVELLGRRGWEALKYWWNLLQYWSQELKNSAVSLLNATAIAVAEGTDRVIEVLQRAGRAILHI 
TA1 --------------------- ---------------------------------------------------------------------------------------------------
p7.10.7 --------------------- ---------------------------------------------------------------------------------------------------
CEM-c11 --------------------- --------S------------------------------------------------------------------------------------------
CEMAX --------------------- --------S------------------------I----------------------------------------T------------------------
721        |         |         |       760         |         |         |       800         |         |         |       840
R3A PRRIRQGLERALL*    
TA1 --------------
p7.10.7 --------------
CEM-c11 --------------
CEMAX --------------
V1/V2 
V3 
V4 V5 
gp120       gp41       
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Figure 2-5. Effects of CEMAX-c7 mutations on wildtype R3A utilization of the R5-
NT/CD4 chimeric coreceptor in cell-cell fusion and replication assays. (A) Fusion 
activity of R3A Env and mutants in a cell-cell fusion assay. Percent of CD4+R5NT only 
fusion was calculated by normalizing to each envelope’s fusion with CD4 and CCR5 
expressing QT6 cells. Background fusion levels with QT6 cells expressing only GFP 
were subtracted prior to normalization. The data shown are the means of three 
experiments plus the standard errors of the means (SEM).  
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Figure 2-6. Virus growth using SupT1-derived cell lines to test R5-NT/CD4 
chimeric coreceptor usage. Growth curves of recombinant NL4-3 viruses containing 
R3A, pre-adaptation Dbl (Dbl-PRE) and Quad (Quad-PRE) clones, adapted swarms and 
representative clones (Dbl cl-1 and Quad cl-4) in (A) A66/CCR5 and (B) A66/R5NT cells. 
RT activity in culture supernatants was measured at the indicated time points. Results 
from a representative experiment are shown. RT activity assay performed by Andrea 
Jordan. 
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Figure 2-7. Sequence alignment of R3A, Dbl and Quad clones pre- and post-
adaptation. Dbl cl-1 maintained the two original gp41 mutations in the FP, but contained 
five new point mutations in gp120 and three others in gp41 compared to the Dbl-PRE 
sequence. Quad cl-4 also maintained three of the four gp41 mutations compared to 
Quad-PRE, with a Val-to-Ile mutation and Ala-to-Thr mutation in gp41 and three others 
in gp120. HxB2 numbering is presented. Locations of gp120 variable domains (V1-V5) 
and gp41 functional domains are indicated (FP, fusion peptide; HR1, heptad repeat-1; 
HR2, heptad repeat-2; MSD, membrane spanning domain; CT, cytoplasmic tail).  
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Figure 2-8. Minimum set of Env mutations for R5-NT/CD4 usage for R3A and 
heterologous HIV-1 Envs. (A) Replication of R3A Env viruses bearing four (4x) or five 
(5x) gp41 mutations required for R5 N-terminus only usage in A66/CCR5 and A66/R5NT 
cells, compared to R3A and Quad cl-4 viruses. RT activity in culture supernatants was 
measured at the indicated time points. Results from a representative experiment are 
shown. RT activity assay performed by Andrea Jordan. (B) Comparison of heterologous 
HIV-1 Envs containing gp41 mutations that confer R5-NT/CD4 fusion. Percent of 
CD4+R5NT fusion was calculated by using luciferase activity normalized to each 
parental envelope’s fusion with CD4+CCR5 expressing QT6 cells. Background fusion 
levels with QT6 cells expressing only GFP were subtracted prior to normalization. The 
data shown are the means of three experiments plus the standard errors of the means 
(SEM). 
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DISCUSSION 
The HIV-1 Env engages in a series of protein-protein interactions with host receptors. 
After CD4 binding, the gp120 bridging sheet and base of V3 engages the coreceptor N-
terminus, and the distal portion of V3 associates with the coreceptor extracellular loops. 
Following coreceptor binding, gp41 reorganizes and initiates membrane fusion. Studies 
that explore the cooperative contributions of the coreceptor N-terminus and ECL 
interactions suggest themes of flexibility involving increased dependence on the N-
terminus attributable to a truncated V3 loop [129, 159, 166, 183] or gp120 mutations 
enabling the use of a coreceptor lacking an N-terminus [152, 176–178]. Although the two 
principal components of coreceptor engagement have been well defined, the transition 
states that occur post-binding and the molecular information that is communicated to 
gp41 for triggering are unknown.  
 
We previously described three sequentially derived R3A variants, designated TA1, ∆V3-
X4, and CEM-c11 [2, 4, 129, 183]. The ability of TA1 Env to utilize CXCR4 appeared to 
be lost as a result of a V3 loop truncation [4, 129]. We reported on the determinants for 
re-acquisition of CXCR4 tropism by deriving a variant that was further adapted to infect 
CEM cells [2, 183]. All Envs contained truncated V3 loops, albeit with different lengths, 
and exhibited resistance to small molecule coreceptor antagonists known to have 
binding sites defined by coreceptor membrane spanning domains [129, 183]. Our 
findings suggested that a truncated V3 confers weaker interactions with the coreceptor 
ECLs and that this was compensated for by increased dependence on the coreceptor N-
terminus for entry. To more precisely identify critical factors that control gp120-CCR5 
interactions, Platt et al. isolated and characterized HIV-1 variants of the JRCSF strain 
that were adapted to use CCR5 lacking the first 18 residues of the N-terminus (termed 
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CCR5Δ18) [152, 178]. In a complementary manner, we developed a model to further 
explore the contribution of the BS/N-terminus interaction to coreceptor engagement by 
creating a novel chimeric coreceptor that expresses the first 27 amino acids of the 
CXCR4 N-terminus fused to a CD4-based anchoring molecule. A CCR5 chimera 
expressing only the first 19 residues of the N-terminus fused to the same CD4 anchor 
was also created. SupT1 cells that lack CXCR4 (termed the A66 cell line) were used to 
create A66/X4NT and A66/R5NT cell lines that express the X4-NT/CD4 and R5-NT/CD4 
constructs, respectively. CEM-c11 was adapted to replicate in the A66/X4NT cell line 
with a severely truncated V3 loop [2]. The adapted variant, designated CEMAX, 
exhibited changes localized exclusively in gp41 and maintained the truncated V3. This 
was a proof of concept that 1) gp120-coreceptor interactions could be dissociated as 
was demonstrated by the previously described CCR5Δ18 coreceptor [152, 178] and 2) 
that a virus could be adapted to use this minimal “N-terminus only” coreceptor construct. 
The acquisition of mutations in gp41 was surprising, given that gp120 drives coreceptor 
interactions. By studying how these mutations affected gp120-coreceptor interactions, 
we reasoned we might learn something about inter-domain interactions within the Env 
complex. However, it is likely that CEMAX’s truncated V3 loop may have compromised 
Env trimer architecture, precluding an appropriate assessment of the structural basis for 
this phenotype. Therefore, R3A Envs with intact V3s and combinations of these gp41 
mutations were assessed in functional assays.  
 
Determinants for “N-terminus only” usage were located in the gp41 ectodomain and 
included CEMAX mutations in the FP (F516I and G524V) and HR2 (I646L). A change 
from a highly conserved alanine to a valine at position 512 that was acquired by TA1 
[129] remained stable through the derivation of CEMAX [2, 183]. We hypothesized that 
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A512V functioned cooperatively with the other two FP changes and included this 
mutation in our analysis. However, even in combination, these four changes conferred 
only 40% of R3A’s ability to use the R5-NT/CD4 construct (and negligible fusion on the 
X4-NT/CD4 construct, data not shown) in cell-cell fusion assays, and viruses containing 
two (pre-adapted Dbl, or “Dbl-PRE”) or four (pre-adapted Quad, or “Quad-PRE”) of these 
changes in env were unable to replicate in A66/R5NT cells. The overexpression of Env 
and receptors in the context of a cell-cell fusion assay can contribute to the detection of 
low-efficiency interactions that are otherwise insufficient to mediate infection in T cell 
lines. Although we cannot exclude the possibility that previously acquired gp120 and 
gp41 mutations that were maintained in the CEMAX env were relevant for the N-
terminus only gain of function, we suspected otherwise. Because CEM-c11 virus was 
unable to replicate in A66/X4NT cells, we hypothesized that the gp41 mutations acquired 
by this env played a central role in conferring this phenotype. Therefore, Dbl- and Quad-
PRE viruses were adapted to replicate efficiently in A66/R5NT cells. 
 
Two Envs were derived, Dbl cl-1 and Quad cl-4, both of which exhibited distinct gp120 
and HR2 mutations, yet common evolutionary pathways in the N-terminal region of 
gp41. It is unknown what role the gp120 mutations play in the acquisition of N-terminus 
only usage, although some of these Env mutations were reported in previous studies of 
V3-truncated variants with increased dependence on the coreceptor N-terminus. Dbl cl-1 
contained five point mutations (C13Y, T142I, N187S, T345I, and T458I) and Quad cl-4 
contained four point mutations (R15H, M149I, T189S, and A286T) in gp120. The N187S 
mutation in Dbl cl-1 removed an N-linked glycan from V1/V2, likely impacting trimer 
packing and neutralization sensitivity by monoclonal antibodies. A conserved amino acid 
mutation, T345I, in C3 near the base of V3, also resulted in the loss of an N-linked 
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glycosylation site in Dbl cl-1 Env. Of particular note, Dbl cl-1 gained an A512V mutation 
that was initially engineered in Quad-PRE env before adaptation. Interestingly, in 
structure/function studies that investigated the determinants for regaining efficient CCR5 
usage by TA1, the T345A and A512V mutations were shown to be largely responsible 
for enhancing replication in CCR5 cells similar to TA1 levels [4, 129]. A pseudovirus 
bearing the same mutations had enhanced sensitivity to maraviroc, monoclonal 
antibodies, and sera. The Met149 in V1/V2 was mutated in Quad cl-4 (and in a 
previously derived R3A variant [183]), but this conservative mutation likely does not 
contribute to N-terminus only usage. Although we did not formally investigate any of 
these gp120 changes, we suggest they play a role in viral fitness and/or trimer stability 
and that instead, the gp41 mutations are poised to play a pivotal role in conferring the 
ability to replicate in A66/R5NT cells.  
 
The A512V, F519I, and G524V mutations in the FP were either maintained or evolved to 
become more hydrophobic in Dbl cl-1 and Quad cl-4, suggesting that the FP was under 
selection pressure for N-terminus only usage. All three FP changes involved the 
conservative substitution of hydrophobic residues, consistent with their location in the 
FP, and each introduced a C-β branched amino acid (Val or Ile). The majority of viruses 
in the Los Alamos Sequence Database contain an Ala or Gly at position 512 and 524, 
respectively. However, Ile519 is a naturally occurring polymorphism that was enriched 
during adaptation to N-terminus only usage. No virus containing all three altered 
residues has been recorded (wwww.hiv.lanl.gov/, as of 09.19.2016), indicating that their 
occurrence in N-terminus only mutants did not arise by chance and implying these FP 
changes may collectively affect fusion efficiency of these Env clones. Intriguingly, Dbl cl-
1 and Quad cl-4 both contained an alanine-to-threonine mutation at position 541 that 
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was also acquired by a V3-truncated R3A variant that we described earlier [183]. This 
finding suggests that the region flanking HR1 is also likely involved in conformational 
changes that occur after receptor binding, consistent with recent biophysical studies of 
the trimer [91, 127, 136, 137, 169, 220, 235]. While the FP and HR1-flanking mutations 
were shown to confer replication competence in A66/R5NT cells, the addition of a fifth 
mutation in HR2 (I646L) correlated with increased fusion on the R5-NT/CD4 construct 
over wildtype CCR5 fusion activity and more rapid viral replication in A66/R5NT cells. 
Because Quad cl-4 maintained this residue after adaptation and viral infection assays, it 
is possible that the HR2 change not only contributes to N-terminus only usage, but also 
viral fitness. Importantly, although Dbl cl-1 and Quad cl-4 acquired isoleucines at 
positions 524 and 512, respectively, during their derivation, no new mutations in env 
were acquired at the conclusion of the 4x and 5x viral growth assay. Thus, our findings 
suggest that these five CEMAX gp41 mutations were sufficient to confer efficient N-
terminus only usage. This observation is explained and explored in further detail in 
Chapter 4. In an attempt to extend our observations for N-terminus only usage, striking 
similarities were observed in cell-cell fusion assays using heterologous HIV-1 envs 
containing analogous gp41 mutations. Four mutations (A512V, F519I, G524V, and 
A541T) could confer over 100% of the CCR5-mediated fusion activity to the clade A 
BG505 env. Likewise, five mutations introduced in clade B YU2 env, including I646L in 
HR2, were sufficient for R5-NT fusion; however, this activity was not sufficient to permit 
a YU2 virus to replicate in SupT1 cells expressing CCR5 (data not shown). This 
discrepancy likely results from Env mutations that affect YU2 viral assembly, replication, 
or trimer stability. Although we did not investigate determinants that were sufficient to 
mediate YU2 and BG505 infection, we did show that this gain of function was not 
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restricted to R3A-based variants and that the phenotype could be extended to 
heterologous HIV-1s.  
 
How changes in gp41 alter the gp120-CCR5 interaction to confer N-terminus only usage 
remains to be understood. We note, however, that even mutations in the gp41 
cytoplasmic tail can enhance interactions with CCR5 and confer resistance to the gp41 
inhibitor enfuvirtide [227]. Furthermore, Anastassopoulou et al. reported that three FP 
changes alone imparted resistance to the CCR5 antagonist, vicriviroc, that targets the 
gp120-ECL interaction [7, 8]. These resistance mutations are similar (G516V and 
M518V) or identical (F519I) to those acquired in the FP of N-terminus only Envs. Berro 
et al. reported that these same vicriviroc resistant mutants remained highly resistant to 
CD4i monoclonal antibodies [15], implying that the CD4i epitope did not become 
constitutively exposed on the native trimer and that the FP changes affected Env 
topology differently than anticipated. Whether gp41 changes from N-terminus only Envs 
affect the global architecture of the trimer and expose elements required for CD4 or 
coreceptor binding has yet to be determined. Furthermore, the rearrangements that 
trigger the release of the FP upon coreceptor binding are unknown, but functional 
analysis of CCR5Δ18-adapted JRCSF variants showed that adaptive changes in the V3 
loop facilitate triggering of fusogenic conformational changes in gp41 for membrane 
fusion [152, 178]. These data suggested that there was a lowered threshold for the 
release of gp41 and the chain of conformational changes that are required for fusion. 
Therefore, we hypothesize that the gp41 changes of N-terminus only variants may also 
function in this manner. Although several trimer structures have been solved, it still 
remained unclear why these gp41 changes can confer this sub-threshold triggering 
phenotype. In the next chapter, I will explore various properties of Env, including 
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antigenicity and fusion efficiency, in an attempt to identify the N-terminus only 
mechanism and describe a recently solved CD4-activated trimer structure of HIV-1 that 
features newly formed domains, providing substantial context for how these N-terminus 
only mutations confer the phenotype.  
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CHAPTER 3 
 
 
CHARACTERIZATION OF VARIANTS OF HIV-1 THAT USE THE CCR5 AMINO-
TERMINUS LACKING EXTRACELLULAR LOOPS 
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ABSTRACT 
CCR5 and CXCR4 engagement by HIV-1 envelope glycoprotein (Env) is composed of 
two distinct interactions involving i) the gp120 bridging sheet and base of V3 engaging 
the coreceptor N-terminus and ii) the V3 crown interacting with coreceptor extracellular 
loops (ECLs). HIV-1 variants have been previously derived that can mediate membrane 
fusion using CD4 and an N-terminus truncated CCR5. Using the dual-tropic virus HIV-
1R3A, we previously derived two viruses, Dbl cl-1 and Quad cl-4, that can replicate in 
CD4+ cells expressing the first 19 amino acids of CCR5 fused to a CD4-based 
membrane anchor in the absence of ECLs (R5-NT/CD4). The determinants for this gain 
of function were localized to the fusion peptide, heptad repeat-2, and a gp41 membrane 
proximal region flanking heptad repeat-1. Here, we extend these studies to further 
characterize Quad cl-4 and a variant of this mutant with five critical gp41 mutations, 
designated as 5x, which can mediate growth in CD4+ R5NT/CD4+ cells. Surprisingly, 
R3A, Quad cl-4, and 5x were equally sensitive to gp120 and gp41 antibody 
neutralization, CCR5 antagonists, and heat treatment. The loss of sensitivity to a fusion 
inhibitor by the mutant Envs, implied that interactions with the CCR5 N-terminus are 
sufficient for triggering conformational changes in the gp41 subunit of Quad cl-4 and 5x 
Envs, but not in wildtype Env. We provide structural context to these observations by 
introducing a recently solved "pre-fusion intermediate" structure that is the final 
conformational state before gp41 release and that only requires coreceptor engagement 
to release gp41. The N-terminus only mutations we mapped align with structures that 
form upon CD4 binding. We propose a model in which the adaptive gp41 mutations 
enable mutant Envs to more readily release the hold on gp41 at a sub-threshold level 
upon interaction with the R5-NT/CD4 coreceptor construct that is sufficient to drive 
membrane fusion.  
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INTRODUCTION 
HIV-1 envelope glycoprotein (Env) initiates infection by sequential binding of the host 
receptor CD4 and a coreceptor (CCR5 or CXCR4). Engagement of coreceptors by Env 
is composed of two distinct interactions. The base of the V3 and bridging sheet (BS) 
engage the coreceptor’s N-terminus, while the V3 crown engages the coreceptor’s 
second extracellular loop (ECL). The release of potential energy upon CD4 binding has 
been previously reported [92]. A second energy barrier for coreceptor binding may exist 
that enables the release of gp41 and the formation of the thermostable six-helix bundle. 
While membrane fusion has been studied extensively [72, 237, 241], the initiation of 
rearrangements that occurs after gp120 engages the coreceptor and the mode of 
communicating molecular information that drives the formation of intermediates of the 
fusion process are unclear. 
 
To evaluate the contribution of the BS/NT interaction in isolation, we created novel 
constructs that expressed the CCR5 (R5) or CXCR4 (X4) N-terminus fused to a CD4-
based anchoring protein. The ability of an HIV-1 with a severely truncated V3 to utilize 
this CCR5-based construct was described as a proof of concept in Chapter 2. 
Determinants for the “N-terminus only” interaction were in the gp41 ectodomain (three in 
the fusion peptide, one flanking heptad repeat-1, and one in heptad repeat-2). We 
examined the importance of these adaptive mutations by introducing them to various 
wildtype HIV-1 envs with intact V3 loops. Unlike wildtype Envs, N-terminus only Envs 
mediated fusion, and in some cases infectivity, with CD4 cells expressing the R5-
NT/CD4 construct. Our findings imply that the N-terminal and ECL domains in CCR5 
have cooperative roles in infection, such that the absence of one site can be 
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compensated for by increased dependency on the other. However, the structural basis 
for this phenotype and the underlying mechanism is unknown.  
 
In this chapter, Quad cl-4 and an R3A Env containing all five gp41 mutations, designated 
as 5x, were further characterized to gain insight into structural and functional alterations 
and possible mechanisms. Both R3A variants showed decreased sensitivity to the C37 
gp41 inhibitor, relative to parental R3A. N-terminus only Envs and R3A showed equal 
sensitivity to the 5-Helix polypeptide gp41 inhibitor, and unexpectedly, to the CCR5 
antagonist, maraviroc. Additionally, all Envs were similarly sensitive to heat treatment as 
measured in a temperature gradient infectivity assay. Intriguingly, R3A variants exhibited 
little in the way of global antigenic changes, except for decreased sensitivity to 
gp120/gp41 interface antibodies that target the fusion peptide (FP). Based on a recently 
solved cryo electron microscopy (cryoEM) trimer structure of a stable CD4-bound 
intermediate, residues required for N-terminus only usage are located in key regions that 
form after CD4 binding and are likely involved with positioning gp41 prior to the release 
of the FP. In this final conformational state before gp41 release, the coreceptor binding 
site was shown to be accessible, and further progression toward the fusogenic form is 
only possibly upon binding to CCR5 or CXCR4 [167]. We propose that the gp41 
adaptations disrupt quaternary constraints on the trimer, lowering the energy thresholds 
for triggering of gp41, and enabling Env to easily bypass critical requirements for full 
coreceptor engagement by engaging only the coreceptor N-terminus before the final 
formation of a six-helix bundle.  
 
MATERIALS AND METHODS 
Chimeric coreceptors. The chimeric R5-NT/CD4 coreceptor was created using 
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overlapping PCR. The first 19 amino acids of CCR5 was fused to the distal 72 residues 
(from Val386 to Ile458) of CD4. 
The following primers were used:  
CCR5 NT Fwd: CACCATGGATTATCAAGTGTCAAGTCC 
CCR5 NT Rev: CATCAATTATTATACATCGGAGCCC 
CD4 Fwd: CATCGGAGCCCGTTCTGCCCACATGGTCC  
CD4 Rev: CGGTTTCAGAAGACATGTAGCCCCATTTGA  
Cells. To investigate the antigenicity of NTO envelopes, the U87 astrocytoma 
cell line was transduced with a CD4 containing lentivirus and then single-cell cloned. A 
CD4-expressing clonal cell line was transduced with either a CCR5 or an R5-NT/CD4 
lentiviral vector and single-cell cloned. The U87 cell lines and the human embryonic 
kidney cell line, 293T, were cultured in Dulbecco’s modified Eagle medium (DMEM) 
supplemented with 10% FBS, 2 mM glutamine, and 2 mM penicillin/streptomycin.  
Generation of pseudotyped viruses. Quad cl-4 and 5x env clones were 
generated as described in chapter two. 293T cells were co-transfected (X-tremegene 9, 
Roche) with a pcDNA3.1 plasmid expressing Env and the Env-deficient HIV-1NL4-3 
genome (pNL4-3R-E-Luc+). Pseudotyped virions were harvested 48 h later and frozen at 
-80 °C.  
Inhibition assays. U87.CD4.CCR5 and U87.CD4.R5NT cells were pre-
incubated with the CCR5 antagonist, maraviroc (kindly provided by Michael Root, 
Thomas Jefferson University), at different concentrations for 1 h at 37°C. Virus was 
added to cells and then incubated for 48 h at 37°C. Cells were assayed for luciferase 
expression and data were fit to a log dose response equation to obtain IC50 values 
(Prism GraphPad software). Viral samples were used to infect U87.CD4.CCR5 and 
U87.CD4.R5NT cells in the presence of varying concentrations of C37 or 5-Helix gp41 
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inhibitor (kindly provided by Michael Root, Thomas Jefferson University). The level of 
viral infectivity was measured after 48 h by assaying for luciferase expression (luciferase 
assay system, Promega). Data were fit to a Langmuir equation to obtain IC50 values 
(OriginLab software).  
Neutralization assays. Neutralization assays were carried out as previously 
described [157]. A subset of mAbs was obtained from the NIH AIDS Research and 
Reference Reagent Program. PGT151 and PGT145 were obtained from the lab of 
Andrew Ward (Scripps Research Institute); VRC34.01 was obtained from the lab of John 
Mascola (Vaccine Research Center, NIH); and ACS202 was obtained from the lab of 
Rogier Sanders (Weill Cornell Medical School). Briefly, pseudotyped virions were pre-
incubated with varying concentrations of monoclonal antibody or sCD4 for 1 h at 37°C, 
and then mixed with U87.CD4.CCR5 cells. Cell mixtures were incubated at 37°C for 48 h 
and then assayed for luciferase production (luciferase assay system, Promega). IC50 
values were calculated as described previously [157].  
Temperature gradient infectivity assay. To investigate the sensitivity of HIV-1 
infectivity to heat treatment, a gradient PCR block (Techne TC-5000 PCR Thermal 
Cycler) was used. 293T-produced pseudoviruses were incubated in parallel in a 96-well 
PCR plate (100 µl per well) on a thermal gradient from 37 to 59°C for 1 h. Following heat 
treatment, samples were mixed with U87.CD4.CCR5 cells and HIV-1 infectivity was 
determined 48 h later. RLU data were background-subtracted using RLU counts 
generated from uninfected cells and normalized according to the 37°C data point. 
Replicate data were curve fitted using a log dose response equation to obtain IC50 
values (Prism GraphPad software).   
 
 61
RESULTS 
N-terminus only Envs are sensitive to maraviroc. Previous experiments with Envs 
containing truncated V3 loops are completely resistant, in cell-cell fusion assays, to 
several CCR5 and CXCR4 antagonists, by being able to recognize the drug-bound 
conformation of the coreceptor. As a consequence of this phenotype, these Envs were 
shown to become more reliant on the CCR5 N-terminus [2, 4, 129, 183]. To validate 
whether the N-terminus only Envs maintained the resistant phenotype with an intact V3, 
we evaluated maraviroc sensitivity in a pseudovirus assay. To do this, novel U87 cell 
lines were created to stably express CD4 and CCR5 (U87.CD4.CCR5, Figure 3-1B and 
D) or the R5-NT/CD4 construct (U87.CD4.R5NT, Figure 3-1C and D). R3A was unable 
to infect U87.CD4.R5NT cells, while R3A mutants infected these cells efficiently (Figure 
3-2). Additionally, we confirmed that maraviroc was indeed unable to bind the R5-
NT/CD4 construct at all indicated inhibitor concentrations, as shown by the preservation 
of infectivity by all pseudovirions (Figure 3-2, inset). R3A was inhibited by maraviroc 
with an IC50 of 4.34 nM. Strikingly, Quad cl-4 and 5x pseudovirions were equally 
sensitive to maraviroc (IC50, 3.98 nM and 2.98 nM, respectivity). Similarly, all three Envs 
exhibited complete sensitivity to the small molecule CCR5 antagonist, TAK-779 (not 
shown).  
 
N-terminus only Envs are less sensitive to neutralization at the gp120/gp41 
interface. Envs with deletions in the V3 stem and crown were exquisitely sensitive to 
several antibodies that target the CD4 binding site, CD4-induced epitope, and the gp41 
membrane proximal external region (MPER), among other sites [4, 129, 166]. The 
acquisition of gp41 mutations in N-terminus only Envs may directly or indirectly affect 
trimer packing, leading to exposure of key epitopes. The sensitivity of N-terminus only 
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Envs to a panel of broadly neutralizing antibodies was evaluated (Figure 3-3). 
Neutralization assays were performed on U87 cells stably expressing CD4 and either 
wildtype CCR5 or the R5-NT/CD4 chimera. Pseudoviruses containing R3A, Quad cl-4, 
and 5x Envs were preincubated with serial dilutions of antibody and then used to infect 
cells. Quad cl-4 and 5x were less sensitive to neutralization by VRC34.01, ACS202 and 
PGT151 monoclonal antibodies, which target the gp120/gp41 interface including the FP 
[22, 75, 126]. Compared to parental R3A, N-terminus only pseudoviruses exhibited 
between 5- and 10-fold decreases in sensitivity to ACS202 and PGT151, respectively, 
with complete resistance to VRC34.01 up to 10  µg/ml. In contrast, there was no change 
in neutralization by 35O22 (reactive with the gp120/gp41 interface that does not include 
the FP) or 10E8 (reactive with an epitope in the gp41 MPER) antibodies. Notably, there 
was also no enhancement in neutralization to any monoclonal antibody targeting gp120, 
including the CD4 binding site (VRC01), a V3 glycan-dependent (PGT126 and 2G12) or 
CD4-induced (E51) epitopes. All viruses were highly resistant to 17b with IC50s above 
the 100 µg/ml detection threshold (data not shown). PG16 and PGT145 failed to 
neutralize all viruses, likely due to the absence of a critical V1/V2 glycan (N160) in the 
R3A env required for antibody targeting [246]. Compared to parental R3A, Quad cl-4 and 
5x were approximately 3-fold more sensitive to sCD4. Thus, compared to parental R3A, 
Quad cl-4 and 5x exhibited less neutralization sensitivity to broadly neutralizing 
monoclonal antibodies directed against the FP, but were equally sensitive to all other 
gp41 and gp120 antibodies tested, indicating that the quaternary structure of these Env 
trimers are not globally perturbed as a consequence of the gp41 mutations.  
 
There are no global stability differences between R3A and N-terminus only Envs. 
To examine whether the stability of each mutant Env was altered relative to R3A, we 
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incubated Quad cl-4 and 5x pseudoviruses at varying temperatures (37°C, 42°C, 47°C, 
51°C, 53°C, 56°C, 59°C) and measured the loss of infectivity. We treated each of the 
viruses with heat for one hour and infected U87.CD4.CCR5 cells. Data were normalized 
to infectivity at 37°C (Figure 3-4). The pseudotyped viruses were most stable at 37°C 
and were fully inactivated at 53°C and beyond. Quad cl-4 displayed sensitivity at 47°C, 
however this sensitivity was not recapitulated for 5x. The T50, which is the temperature 
corresponding to 50% reduction of infectivity relative to infectivity at 37°C, was similar for 
all viruses (~45-47°C). Thus, although different temperatures produced varying levels of 
inactivation for the three viruses, neither sensitivity nor resistance was consistently 
associated with either Quad cl-4 or 5x viruses. Taken together, these results show that 
the ability of N-terminal only viruses to use CD4 and R5-NT/CD4 is not the result of 
global stability differences of these Env proteins.  
 
Quad cl-4 and 5x are less sensitive to gp41 fusion inhibitors. To assess whether 
fusion kinetics was affected by the gp41 ectodomain mutations, we evaluated the R3A, 
Quad cl-4, and 5x sensitivities to C37 and 5-Helix inhibitors using U87.CD4.CCR5 and 
U87.CD4.R5NT cells. R3A was inhibited by C37 on CCR5 cells with an IC50 of 25.8 nM. 
In contrast, Quad cl-4 and 5x showed decreased sensitivity to C37 inhibitor (IC50, 79.1 
nM and 48.8 nM, respectively) (Figure 3-5A and C). All viruses were comparably 
inhibited by 5-Helix on U87.CD4.CCR5 cells. 5x exhibited a similar C37 IC50 (37.2 nM) 
as Quad cl-4 (20.4 nM) on U87.CD4.R5NT cells, however 5x was roughly 3-fold less 
sensitive to 5-Helix on R5NT cells, compared to Quad cl-4 at an IC50 of 14 nM (Figure 3-
5B and C). Collectively, these findings suggest that N-terminus only Envs have a shorter 
kinetic window for C37 binding, compared to parental R3A, and the transition to forming 
fusion the irreversible fusion intermediate occurs faster.  
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Figure 3-2. Sensitivity to the CCR5 antagonist maraviroc.  Inhibition of R3A, Quad cl-
4, and 5x pseudoviruses by the indicated concentrations of maraviroc in U87.CD4.CCR5 
and U87.CD4.R5NT cells. Relative infectivity was calculated by using luciferase activity 
normalized to infectivity of U87.CD4.CCR5 cells with no inhibitor. Inset shows relative 
light units (RLUs) of pseudoviruses on U87.CD4.R5NT cells at varying concentrations of 
maraviroc. Means from three experiments plus the standard error of the means are 
shown. 
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Figure 3-3. Neutralizing activities of Env monoclonal antibodies against HIV-1 
pseudotypes expressing wildtype or N-terminus only Envs. HIV-1 pseudoviruses 
bearing wild type or mutated Envs were pre-incubated with titrated mAbs or sCD4, then 
added to U87.CD4.CCR5 cells. IC50s for each combination are shown and color-coded 
according to magnitude (<0.01ug/mL red, 0.01-0.1 ug/mL orange, 0.1-1 ug/mL yellow, 1-
10 ug/mL green, >10 ug/mL grey).  
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Figure 3-4. Sensitivity of HIV-1 R3A and N-terminus only variants to heat.  The 
effect of temperature on infectivity was assessed for R3A, Quad cl-4, and 5x. Viruses 
were incubated at varying temperatures for one hour before infecting U87.CD4.CCR5 
cells. Data were normalized to infectivity at 37°C. 
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Figure 3-5. Sensitivity of HIV-1 R3A and N-terminus only Envs to gp41 fusion 
inhibitors. (A) Inhibition of R3A and N-terminal using pseudotyped viruses by the 
indicated concentrations of C37 on U87.CD4.CCR5 (left) and U87.CD4.R5NT (right) 
cells. (B) Inhibition with 5-Helix inhibitor on U87.CD4.CCR5 (left) and U87.CD4.R5NT 
(right) cells. (C) C37 and 5-Helix IC50s for each pseudovirus infecting either 
U87.CD4.CCR5 or U87.CD4.R5NT cells. The means of three experiments plus the 
standard error of the means are shown 
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Figure 3-6. Structures of gp41 in the pre-fusion ground state and CD4-bound 
intermediate state. (A) Structural rearrangements in gp41 between the pre-fusion and 
CD4-bound states include repacking of trimeric HR1. (B) Space-filling model with the FP 
pointing away from the trimer core in the ground state (left panel) that rearranges into a 
CD4-induced pocket near the trimer core (right panel). The FPPR/HR1N region forms a 
stable helix (light pink ribbon) that packs against HR2 from two different protomers 
(magenta and green). Ala512, Gly524, and Ala541 make contact with gp41 residues 
(magenta), whereas Phe519 interacts with gp120 residues of the pocket (teal). Models 
constructed by Gabriel Ozorowski and Andrew Ward.  
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DISCUSSION 
Utilization of the CCR5 and CXCR4 coreceptors by HIV-1 involves interactions between 
1) the base of V3 and the adjoining BS and the coreceptor N-terminus and 2) the tip of 
V3 and domains formed by the coreceptor ECLs. Since coreceptor binding is crucial for 
triggering conformational changes needed for fusion, disrupting the V3/ECL interactions 
can impede viral entry. We previously reported that V3-truncated R3A Envs selectively 
reduced the reliance on the V3/ECL interaction, resulting in the resistance to coreceptor 
antagonists, and that these Envs became more dependent on the coreceptor N-terminus 
interaction [2, 4, 129, 166, 183]. We continued to explore the individual contribution of 
the BS/NT interaction to coreceptor engagement by creating CD4-based coreceptor 
chimeras that only express the first 19 residues of R5, or 27 residues of X4, in the 
absence of ECLs. A virus, termed CEMAX, containing a severely truncated V3 was 
derived that could replicate to high levels in cells expressing the X4-NT/CD4 chimera 
without losing the ability to replicate efficiently in CD4 cells expressing wildtype X4 [2]. 
Determinants for this gain of function were located in the gp41 ectodomain and because 
this was a proof of concept for isolating coreceptor interactions, we extended this 
phenotype to an R3A env with an intact V3 and other heterologous HIV-1 envs. In this 
chapter, we assessed some properties that define N-terminal only Envs and designed 
our analysis to identify generalizable differences in sensitivity to: coreceptor antagonists, 
broadly neutralizing antibodies, heat treatment, and gp41 fusion inhibitors.  
 
Rather than directly intercepting the interaction between gp120 and coreceptor, CCR5 
antagonists bind to a hydrophobic pocket formed by the coreceptor transmembrane 
regions and alter the ECL conformations that are required to engage distal portions of 
V3 [117, 236]. We anticipated that N-terminus only Envs, such as Quad cl-4 and 5x, 
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would become completely resistant to these inhibitors by exclusively interacting with the 
unaltered CCR5 N-terminus. Surprisingly, our results were not consistent with our model 
of exclusive dependence on the N-terminus of a full-length coreceptor, because Quad cl-
4 and 5x were completely sensitive to maraviroc. A previously derived variant of R3A 
with a truncated V3 was shown to be completely resistant to CCR5 antagonists by 
increasing dependency on the CCR5 N-terminus. It was determined that the V3 loop 
deletion alone was largely responsible for CCR5 antagonist resistance, regardless of the 
presence or absence of any adaptive mutations, such as the alanine-to-valine change in 
the N-terminal residue of gp41 [4, 129]. Quad cl-4 and 5x envs contained intact V3s and 
the same A512V mutation, among other changes. Therefore, we hypothesize that N-
terminus only viruses are still capable of utilizing the ECLs, if available, and that in the 
context of maraviroc-bound coreceptor, the Quad cl-4 and 5x Envs become sensitive. 
Although the structural basis for this observation is still unclear, it is also intriguing to 
hypothesize that while maraviroc acts via an allosteric mechanism in which the ECL 
conformations are altered, the N-terminal domain may be comparably affected by 
binding, resulting in two unavailable domains that are important for engagement by 
gp120. Taken together, both models we propose for this phenotype are based on the 
plasticity of Env-coreceptor interactions, but our structure-function studies will need to be 
further developed, as is outlined in Chapter 5.  
 
The V3 truncated Envs we described previously [4, 129, 166] exhibited enhanced 
neutralization sensitivity to monoclonal antibodies that target key epitopes in gp120 and 
gp41, likely due to the shortened V3 loop that exposed more conserved domains in the 
gp120 core. Although a full investigation of the antigenicity profile of CEMAX was not 
performed, we examined how adaptive mutations affected the neutralization sensitivity of 
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Quad cl-4 and 5x to monoclonal antibodies, compared to wildtype R3A. Unexpectedly, 
the CD4 binding site, V3, and CD4-induced epitopes remained equally sensitive to 
antibodies. Mutant Envs containing FP mutations were however resistant to a panel of 
gp120/gp41 interface broadly neutralizing antibodies that recognize the FP, including 
PGT151, ACS202, and VRC34 [22, 75, 101, 126]. Quad cl-4, 5x, and wildtype R3A 
remained sensitive to the 35O22 antibody that recognizes a distinct gp120/gp41 contact 
site, and to the 10E8 antibody directed against the membrane proximal external region 
of gp41. Overall, changes in gp41 did not cause global changes in Env, as was also 
described by Berro and colleagues who studied Envs with hydrophobic point mutations 
in the FP [15]. We did observe that Quad cl-4 and 5x were 3-fold more sensitive to sCD4 
relative to R3A. The lack of global effects on the surface of Env suggest that the trimer 
architecture likely remains in a closed conformation, and therefore we hypothesize that 
these changes have instead affected the “internal wiring” of Env involving conformational 
rearrangements. The ability to transition from a high to lower energy state upon receptor 
binding was described to modulate antibody-mediated neutralization and the mechanism 
of CD4-independence [92]. Although a chemokine receptor-independent HIV-1 has not 
been described, we propose that the gp41 changes in N-terminus only Envs facilitate the 
transition to overcome the final barrier to release gp41.  
 
The acquisition of gp41 mutations were hypothesized to improve the efficiency of N-
terminus only receptor binding and compensate for the lack of ECLs, which led us to 
examine the properties of fusion and the properties that may affect conformational 
changes that occur following coreceptor binding. Differences in Env stability affect 
conformational changes in the entry process, and alterations in trimer stability can be 
evaluated by sensitivity to inactivation at varying temperatures [133]. Although there 
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were some differences in heat sensitivity between R3A and Quad cl-4 and 5x Envs, the 
T50 values were largely identical. Therefore, thermal sensitivity did not confer global 
instability and is unlikely to account for the mechanism of N-terminal only usage. We 
also tested whether the rate of fusion was altered because three of the five gp41 
mutations that were important for the gain of function were located in the FP. A previous 
study using avian sarcoma/leukosis virus subtype A (ASLV-A) as a model for Type I 
fusion, identified mutations in HR1 and a segment in the TM subunit near the 
hydrophobic fusion peptide that diminished sensitivity to enfuvirtide, an HR2 peptide 
inhibitor [6]. Indeed, some mutations introduced more hydrophobic residues in this 
region, and were shown to alter the requirements for envelope triggering, likely reducing 
the activation threshold and permitting expanded tropism. Quad cl-4 and 5x Envs 
exhibited less sensitivity to the gp41 HR2-based inhibitor, C37, in relation to R3A upon 
infection of U87.CD4.CCR5 cells. The N- and C-termini of gp41 become transiently 
susceptible to inhibitors within a kinetic window between CD4 binding and 6HB 
formation, but these gp41 regions are exposed asymmetrically [113]. 5-Helix inhibitor 
targets the gp41 C-terminal region of a short-lived intermediate state. Therefore, it is 
perhaps unsurprising that inhibition of parental and mutant pseudoviruses were equally 
sensitive to this kinetically restricted inhibitor during infection of U87.CD4.CCR5 cells. 
Because R3A virus is unable to infect U87.CD4.R5NT cells, we could only compare C37 
and 5-Helix sensitivities between Quad cl-4 and 5x viruses. These Envs displayed 
similar C37 IC50’s in R5NT cells. Conversely, 5x was 3-fold less sensitive to 5-Helix, 
compared to Quad cl-4. We hypothesized that cooperative interactions between the 
gp120 and gp41 changes in Quad cl-4 may have structural implications for the exposure 
of HR2, prolonging the kinetic window for 5-Helix binding. Nonetheless, our findings 
imply that in the context of wildtype CCR5 engagement by N-terminus only Envs, the 
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kinetic window in which the HR1 binding site is exposed is shortened and that the 
minimal requirement for CCR5 N-terminal engagement is sufficient to trigger gp41.  
 
Given the lack of massive changes on the surface of mutant trimers as determined by 
antigenicity and functional stability studies, we referred to recently emerging structural 
studies that could reveal a mechanism for how these gp41 changes likely facilitate 
subthreshold triggering. X-ray and cryoEM maps have implicated important gp41 
domains that play a role in constraining the ground state in a closed conformation [13, 
91, 112, 127, 136, 137, 169, 220, 235]. During our genetic analysis of N-terminus only 
Envs, Ozorowski and colleagues had solved the first structure of a CD4-bound 
solubilized trimer intermediate that revealed fascinating insights into a complex network 
of allosteric rearrangements that propagate through g120 and gp41, including the 
formation of the coreceptor binding site that is primed for coreceptor engagement. 
Conformational changes in gp41 were shown to consist of the formation of a stable helix 
consisting of the fusion peptide proximal region (FPPR) and the N-terminal portion of 
HR1 (HR1N). Pre-fusion stabilizing interactions between gp41 and gp120, like the triple 
tryptophan clasp remained intact in this state, however new networks of interactions 
were shown to form to stabilize the trimer. HR1N was described to move away from the 
trimer core and pack against HR2, and the C1 and C5 domains of gp120 were shown to 
translocate in the same direction to avoid clashing with HR2 of a different protomer 
[167]. In pre-fusion solubilized structures, the FP is solvent exposed, preventing Ala512 
and Phe519 from contacting residues of the trimer [127, 136, 137, 169, 220]. The CD4-
bound conformation creates a large hydrophobic pocket at the gp120/gp41 interface 
near the trimer core that is now occupied by the FP, providing a favorable position for 
triggering the formation of the pre-hairpin intermediate following coreceptor engagement 
 75
[167]. Four mutations that confer N-terminus only usage map to key gp41 domains that 
only form upon CD4 binding (A. Ward, personal communication and Figure 3-6). In 
contrast, the HR2 helix, containing the Ile646, is mostly pre-formed in the pre-fusion 
structure [127, 136, 137, 169, 220]. In the intermediate state, the Phe519 makes 
contacts with Ile491, Ala205, and Thr244 of gp120, while Ala512 interacts with Arg588 of 
HR1. The glycine at position 524 interacts with Ala662 in the membrane proximal region 
of gp41, just preceding the cutoff at position 664 of the solubilized trimer. The stable 
FPPR/HR1N helical region contains the Ala541, which engages with Leu592 
and Ile/Leu595 of a neighboring HR1 domain. Given these findings, the “pre-fusion 
intermediate” structure is not yet capable of triggering, but is the final conformational 
state before gp41 release. The newly formed domains are poised to react after a 
minimal interaction with the coreceptor N-terminus that is sufficient for the final step of 
gp41 release. By using structural clues from this CD4-bound intermediate, we propose a 
mechanism in which the A512V, F519I, and G524V mutations likely disrupt the CD4-
induced hydrophobic pocket that is formed at the gp120/gp41 interface. The A541T and 
I646L mutations located in the FPPR/HR1N helix and HR2, respectively, likely contribute 
to destabilizing the gp41 helical collar that constrains the gp120 C1 and C5 domains, 
such that a sub-threshold triggering event is sufficient to release the FP from its 
protected chamber. Thus, this gain of function phenotype brings together the structural 
snapshots and functional elements of receptor binding and provides valuable insights 
into the allosteric triggers that enable transitioning into stable intermediates.   
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CHAPTER 4 
 
 
THE ROLE OF TETHERIN IN ENHANCING VPU-DEFICIENT HIV-1 INFECTION OF 
CD4+ CELLS EXPRESSING THE CCR5 N-TERMINUS IN THE ABSENCE OF 
EXTRACELLULAR LOOPS 
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ABSTRACT 
Tetherin is a late-acting host restriction factor that captures budding virions at the 
plasma membrane and may also promote host innate anti-viral immune responses. The 
HIV-1 accessory protein, Vpu, antagonizes tetherin by targeting it for proteosomal or 
lysosomal degradation. Although tetherin can inhibit viral release and disrupt cell-free 
viral transmission, its impact on cell-to-cell spread of virus is controversial. Cell-to-cell 
transfer of HIV-1 is known to be an efficient mode of dissemination in in vivo settings, 
such as secondary lymphoid tissues. The virological synapse facilitates this process, 
and it has been proposed that the enrichment of tetherin at these sites with formation of 
“tethered” viral aggregates on the cell surface could promote cell-to-cell infection. Having 
derived viruses that can replicate in cells expressing CD4 and only the CCR5 N-terminus 
in the absence of extracellular loops (A66/R5NT cells), we reported that the acquisition 
of specific gp41 mutations was responsible for conferring this gain of function. However, 
during selection of viruses with this phenotype we also noted the appearance of 
mutations that disrupted in the vpu open reading frame, suggesting that there were also 
strong pressures selecting for the loss of this viral protein. In this Chapter we show that 
while fusion using the CCR5 N-terminus requires mutations in gp41, viral replication on 
cells expresseing the CCR5 N-terminus is markedly enhanced in the absence of Vpu. 
We tested the role of tetherin in this effect by disrupting its expression using CRISPR-
cas9 technology and evaluated viruses with and without Vpu. We found that in the 
absence of tetherin, replication of “N-terminus only” viruses on cells bearing the only 
CCR5 N-terminus with CD4 was severely impaired. We propose a model in which 
tetherin, when unopposed by Vpu, can strongly promote a spreading infection of viruses 
with a compromised interaction between Env and coreceptor, most likely through the 
creation of cell-associated aggregates and the facilitation of cell-to-cell transfer. 
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INTRODUCTION  
HIV-1 can enter cells either through a cell-free pathway or by being transmitted by direct 
cell-to-cell contact. Transmission becomes reliant on cell-to-cell spreading when the cell-
free route is experimentally blocked [248]. Therefore, cell-to-cell spread may be 
preferentially utilized if viral fitness costs exist in the context of cell-free transmission in 
in vivo settings, like secondary lymphoid tissues [39, 161]. The virological synapse (VS) 
facilitates a cell-to-cell spreading infection by creating an intra-molecular axis between 
an infected and uninfected cell [39, 102, 109, 199, 204]. Cytoskeleton rearrangements 
ultimately direct assembly and budding of virions toward the target cell at the synaptic 
cleft [25, 102, 109, 110].  
 
Cells express a group of interferon-inducible innate restriction factors to resist viral 
infection, including but not limited to APOBEC3G, TRIM5α, SAMHD1, and tetherin. 
Tetherin is a late-acting host restriction factor that traps and tethers virions at the plasma 
membrane, preventing nascent cell-free viral release [53, 172]. However, HIV-1 has 
evolved the Vpu accessory protein to antagonize this host protein by targeting it for 
proteosomal or lysosomal degradation [53, 64, 87, 105, 148, 155, 221], [163, 164, 223]. 
Vpu also targets newly synthesized CD4 for degradation [146] and inhibits NFκB 
activation [27].  
 
In Chapter 2, we reported the adaptation of an HIV-1 isolate, R3A, to replicate in CD4+ 
cells expressing the CCR5 N-terminus in the absence of ECLs (A66/R5NT cells). Of 
note, in selecting for viruses that exhibited this gain of function, we consistently observed 
stop codons in the open reading frame of vpu that overlaps env. We investigated this 
phenotype in viral growth assays and observed that viruses lacking Vpu mediated 
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strikingly enhanced replication in A66/R5NT cells. There is evidence that Vpu-deficient 
HIV-1 can overcome tetherin-mediated restriction in the context of cell-to-cell 
transmission [90, 107, 175, 206, 229]. Therefore, we considered the possibility that 
tetherin was involved in enhancing cell-to-cell spread of Vpu-deficient viruses in 
A66/R5NT cells. We used this opportunity to employ CRISPR-cas9 technology to ablate 
the expression of tetherin in A66/CCR5 and A66/R5NT cells. Our findings show that 
Vpu-deficient viruses replicated with enhanced kinetics in cells expressing tetherin, but 
viral growth was significantly delayed when tetherin was knocked out. We hypothesize 
that Vpu provides advantages and disadvantages to HIV-1 depending on the cellular 
environment and rather than considering tetherin as only a restriction factor, and we 
propose a model in which tetherin can also modulate the efficiency of transmission by 
enhancing cell-to-cell spread of Vpu-deficient “N-terminus only” viruses and, perhaps 
more generally, with other viruses for which there is a suboptimal interaction of Env with 
CD4 and its coreceptor.  
 
MATERIALS AND METHODS 
Cells. To provide a definitive answer as to whether tetherin has any role to play 
in HIV-1 N-terminus only infection, we knocked out tetherin from A66/R5NT cells, using 
CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats Type II)/Cas9 
technology. Cells were transduced with a lentiCRISPR pseudovirus (kindly provided by 
Paul Bates), which enables simultaneous delivery of a mammalian codon-optimized 
Cas9 nuclease, a single guide RNA (sgRNA) and a puromycin selection marker into 
target cells. Cells were spinfected at 1,200xg for 30 min and incubated with virus for 24 
h. Media was replaced with puromycin-containing medium (0.5 µg/ml) and maintained 
for seven days until recovery. To confirm whether tetherin expression was successfully 
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disrupted, Type I interferon (1,000 U/ml) was used to stimulate a fraction of the parental 
and CRISPR-treated A66/CCR5 and A66/R5NT clones for 24 hours. Cells were then 
stained with PE anti-human tetherin antibody (BioLegend) and analyzed by flow 
cytometry for the loss of tetherin expression. Single-cell clones were derived by limiting 
dilution and expanded. Genomic DNA from lead candidates was extracted and analyzed 
by bulk PCR to confirm the ablation of tetherin gene expression. To pick the appropriate 
clones for viral growth assays, another round of tetherin staining and flow cytometry 
analysis was performed. 
Env cloning, plasmid construction, and mutagenesis. Mutant R3A and 5x 
vpu genes in pcDNA3.1 expression vectors were created using a QuikChange site-
directed mutagenesis kit (Stratagene) following the manufacturer’s protocol. The 
identities of the mutations were confirmed by DNA sequencing. Selected mutants were 
digested with EcoRI and XhoI and ligated to the pNL4-3 HIV-1 genome construct to 
generate recombinant replication-competent viruses. 
Replication-competent viral infection assays. 293T cells were transfected for 
4 h using the calcium phosphate method with pNL4-3 viral backbones bearing env and 
vpu genes to generate infectious molecular clones. Cell supernatants were collected 48 
h later and stored at -80°C. Viral p24 concentrations were determined by an enzyme-
linked immunosorbent assay (Perkin-Elmer). A66-derived cells were inoculated with 
equivalent amounts of p24-containing virus and incubated overnight at 37°C. Cells were 
washed in RPMI medium supplemented with 5% FBS to remove residual virus, and viral 
replication was monitored over time by measuring viral reverse transcriptase (RT) 
activity in the culture supernatants.  
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RESULTS 
Growth of N-terminus only viruses in A66/R5NT cells is facilitated by the loss of 
Vpu. Although the five adaptive mutations acquired and maintained by Dbl cl-1 and 
Quad cl-4 were sufficient for exclusive dependence on the CCR5 NT, we also observed 
the acquisition of a stop codon in the vpu open reading frame of both viruses (Figure 4-
1). To validate that “CCR5 N-terminus only” use is specific to the gp41 mutations and 
that the absence of Vpu is not solely responsible for this gain of function, we compared 
the growth of R3A and R3A Vpu- viruses in A66/CCR5 and A66/R5NT cells (Figure 4-2). 
Both viruses replicated with wildtype kinetics on A66/CCR5 cells, but could not infect 
cells expressing the R5-NT/CD4 construct, while the N-terminus only virus, Quad cl-4, 
replicated efficiently. To further investigate the basis of the loss of Vpu, a stop codon 
was introduced into the open reading frame of vpu at position 12 of an R3A-Env bearing 
virus containing five gp41 mutations (5x Vpu-). This virus replicated with wildtype kinetics 
on A66/CCR5 cells, but reached peak RT levels on A66/R5NT cells approximately 10 
days before 5x (Figure 4-3). Surprisingly, 5x Vpu- and Quad cl-4 viruses exhibited nearly 
identical growth kinetics on A66/R5NT cells, revealing the necessary and sufficient 
genetic determinants in env and vpu for N-terminus only usage (Figure 4-3). In Chapter 
2, bulk sequencing of infected A66/R5NT cells revealed the acquisition of a stop codon 
at position 23 in the 4x vpu transmembrane domain (see Figure 2-8). To determine 
whether there is a preference in acquiring a stop codon in vpu over mutating HR2 (or 
elsewhere in env), we passaged the 4x virus in a 1:10 mix of A66/CCR5 and A66/R5NT 
cells eight times and then in pure A66/R5NT cells another 8 times. Bulk sequencing of 
infected A66/R5NT cells revealed no new changes in env; instead, a stop codon at 
position 30 of vpu was acquired (Figure 4-1). Our data imply that the loss of Vpu is 
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preferred in certain cellular contexts, but that the fifth gp41 mutation in HR2 (I646L) 
facilitates N-terminus only fusion and replication (see Chapter 2).    
 
The presence of tetherin enhances replication of Vpu-deficient N-terminus only 
viruses. We hypothesized that the well-studied interaction between Vpu and the 
interferon-induced host restriction factor, tetherin, was affected in this context. We 
created tetherin-null versions of A66/CCR5 (A66/CCR5 CRISPR) and A66/R5NT 
(A66/R5NT CRISPR) cells using CRISPR-cas9 technology (Figure 4-4). All viruses that 
we tested replicated efficiently in A66/CCR5 CRISPR cells that lacked the expression of 
tetherin (Figure 4-5). However, replication was considerably delayed in A66/R5NT cells 
lacking tetherin, emphasizing the importance of tetherin in promoting replication in the 
absence of Vpu, possibly through cell-to-cell spread. However, we observed the RT 
activity levels of 5x and Quad cl-4 viruses rise after 14 days, while 5x Vpu- viral 
replication continued to remain below the threshold of detection. Bulk sequencing of 
infected cells did not reveal any additional mutations in Quad cl-4 and 5x env and vpu 
that could have accounted for the increase in RT levels.  
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FIGURES 
 
 
 
Figure 4-1. Analysis of N-terminus only Env Vpu sequences. Asterisks indicate stop 
codons in open reading frame of each vpu acquired during adaptation.  
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Figure 4-2. The role of Vpu in N-terminus only usage in the absence of gp41 
adaptive mutations. Replication of R3A viruses with and without functional Vpus in 
A66/CCR5 and A66/R5NT cells, compared to Quad cl-4 virus. RT activity in culture 
supernatants was measured at the indicated time points. Results from a representative 
experiment are shown. RT activity assay performed by Andrea Jordan.  
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Figure 4-3. The impact of the loss of Vpu on HIV-1 N-terminus only viruses. Growth 
of R3A viruses with and without Vpu and gp41 adaptation mutations in A66/CCR5 and 
A66/R5NT cells. RT activity in culture supernatants was measured at the indicated time 
points. Results from a representative experiment are shown. RT activity assay 
performed by Andrea Jordan.  
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Figure 4-4. Novel tetherin-null A66 cell lines that express CD4 and CCR5 or R5-
NT/CD4 chimeric coreceptor. A66/CCR5 (top) and A66/R5NT (bottom) cells treated 
with CRISPR-cas9 technology and single-cell cloned. Clones were interferon-treated for 
24 h to stimulate tetherin expression.  
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Figure 4-5. The role of tetherin in enhancing Vpu-deficient N-terminus only viral 
replication. Viral growth of R3A viruses with and without functional Vpus and gp41 
adaptation mutations in tetherin-null A66/CCR5 (top) and A66/R5NT (bottom) CRISPR 
cells. RT activity in culture supernatants was measured at the indicated time points. 
Results from a representative experiment are shown. RT activity assay performed by 
Andrea Jordan.  
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DISCUSSION 
In Chapter 2, we described the derivation of variants of the dual-tropic, Clade B isolate 
R3A that can fuse and replicate with cells expressing CD4 and a construct containing 
the first 19 residues of CCR5 attached to a CD4-based anchoring molecule (R5-
NT/CD4). Because the vpu open reading frame overlaps that of env, we created pNL4-3 
infectious molecular clones bearing Dbl cl-1 and Quad cl-4 envs and their accompanying 
vpu genes. In addition to analyzing adaptive sequence changes in env, we also 
investigated vpu. We noted stop codons in the vpu open reading frames of Dbl cl-1 and 
Quad cl-4 accompanied by the gp120 and gp41 changes in these R3A variants. Our 
findings show that mutations in the gp41 fusion peptide (FP) (A512V, F519I, G524V), 
HR2 (I646L), and a region flanking the start of HR1 (A541T) correlated with the 
acquisition of N-terminus only usage. We confirmed that the loss of Vpu alone was 
unable to confer CD4-dependent infectivity to parental R3A on cells expressing the R5-
NT/CD4 construct, and that the gain of function is specific to the gp41 mutations. 
However, the replication of an R3A virus bearing five mutations (5x virus) in A66/R5NT 
cells was markedly enhanced by the loss of Vpu.  
 
Vpu has been shown to antagonize the host restriction factor, tetherin, in infected cells, 
preventing tetherin-mediated crosslinking of virions at the plasma membrane. Evidence 
suggests that HIV-1 lacking Vpu accumulates at the plasma membrane and within 
intracellular compartments [122]. Jolly et al. demonstrated that Vpu-defective virions 
disseminated faster by cell-to-cell contact in cultured primary CD4+ T cells when cell-
free virus release was restricted in a tetherin-dependent manner [108]. Given this finding 
and the well-studied interplay between Vpu and tetherin, we used this opportunity to 
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study whether the enhancement of replication of Vpu-defective N-terminus only viruses 
was dependent upon tetherin-mediated cell-to-cell spread.  
 
The expression of tetherin is primarily upregulated by Type I IFNs, though other IFN-
independent pathways have also been shown to contribute to its expression [9, 53, 59, 
164]. We utilized CRISPR-cas9 technology to disrupt tetherin expression in the A66 cell 
lines that express CCR5 or the R5-NT/CD4 construct. In viral growth assays, N-terminus 
only virus replication was severely delayed in A66/R5NT CRISPR cells. Genomic DNA 
sequencing of each CRISPR-treated cell line revealed a frameshift that caused the 
acquisition of a premature stop codon in the first exon of tetherin, suggesting that 
tetherin expression is completely disrupted. However, RT activity of Quad cl-4 and 5x 
viruses rose above background levels by day 14. It is likely that viral factors could 
compensate for the absence of tetherin and Vpu to mediate R5-NT/CD4 usage, and that 
the acquisition of mutation(s) in other HIV-1 genes impacts this delayed increase in 
replication. 5x virus containing an intact vpu did not infect A66/R5NT CRISPR cells, 
highlighting the influence of tetherin in promoting N-terminus only usage.  
 
Although tetherin potently prevents the release of cell-free virion release, its ability to 
also block cell-to-cell transfer is controversial [32, 108]. Jolly et al. reported that the 
enrichment of tetherin at the VS was a key factor in cell-to-cell spreading [108]. 
Moreover, the depletion of tetherin by siRNA was shown to affect the formation of the VS 
and cell-to-cell transmission by Vpu-defective HIV-1. However, Casartelli and colleagues 
showed that virions produced from cells expressing tetherin were transmitted by cell-to-
cell contact as large aggregates with diminished infectivity [32]. A possible explanation 
for the differences in both studies could be cell-type dependent, where high tetherin 
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expression restricts Vpu-defective HIV-1 cell-to-cell spread, but lower expression does 
not impair, or may even contribute to, viral transmission.  
 
In contrast to the late-acting restriction mediated by tetherin, interferon-induced 
transmembrane (IFITM) proteins inhibit viral entry. The derivation of HIV-1 viruses 
resistant to IFITM proteins resulted in the acquisition of a stop codon in Vpu that was 
shown to enhance HIV-1 replication by promoting cell-to-cell transmission [59]. 
Furthermore, some viruses with high replicative capacity in macrophages contain 
defective vpu genes [70]. Various studies have performed in vitro and ex vivo 
experiments with primary cells or primary isolates, to understand the consequences of 
disrupting Vpu function [70, 107, 204, 206, 208, 209]. Given this, it is tempting to 
speculate on a modulatory role for tetherin in certain in vivo compartments, like 
secondary lymphoid tissue or the brain. In this context, tetherin-mediated cell-to-cell 
spread may increase the efficiency of entry at the VS. Taken together, we propose a 
model in which the loss of Vpu amplifies transmission of virus through cell-associated 
viral aggregates formed by unopposed tetherin. We hypothesize that these aggregates 
can overcome sub-optimal entry conditions, (i.e. cells expressing the CCR5 N-terminus 
in the absence of ECLs) and could have more generalized relevance in promoting 
infection for viruses in which the interaction between the envelope glycoprotein and the 
receptor are suboptimal.  
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OVERVIEW 
HIV-1 entry is composed of a series of protein-protein interactions between Env and host 
receptors, CCR5 (R5) or CXCR4 (X4). The importance of studying HIV-1 coreceptor 
use, particularly CCR5 engagement, is underscored by the transmission of only R5-
tropic strains at the site of infection [211]. Moreover, coreceptor switching to CXCR4 
usage is associated with rapid progression to AIDS [49, 115, 190, 210]. Having a more 
complete understanding of the molecular mechanisms of entry can not only expand and 
diversify the current arsenal of entry blockers, but also has implications for developing a 
vaccine with broadly neutralizing antibodies. Despite extensive research on CD4 binding 
and coreceptor engagement, the mechanism of how domains of gp120 interact with 
those of the coreceptor to trigger the gp41 fusion machinery has yet to be fully 
described. 
 
Coreceptor engagement is composed of two interactions: the bridging sheet and base of 
V3 interacts with the coreceptor N-terminus, while distal portions of the V3 engage ECL2 
of the coreceptor. This thesis examined the contribution of the interaction between Env 
and the CCR5 N-terminus to drive the fusion process, by deriving in vitro variants that 
can use the CCR5 N-terminus in the absence of ECLs. In Chapter Two, we initiated our 
studies with a previously described dual-tropic HIV-1 R3A variant, called CEMAX [2]. 
This virus contained a severely truncated V3 loop and could replicate using CD4 and the 
CCR5 N-terminus in the absence of ECLs. Strikingly, adaptive mutations were located 
exclusively in the gp41 subunit of CEMAX. Through this novel phenotype, CEMAX 
represents a proof-of-concept that the two interactions Env makes with a coreceptor can 
be dissociated. We hypothesized that a similar approach could be taken to isolate a 
virus with an intact V3 loop that mediates “N-terminus only” usage. Two viruses, Dbl-
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PRE and Quad-PRE, containing key gp41 mutations shown to be important for N-
terminus only usage, were separately adapted to replicate in cells expressing CD4 and 
the R5-NT/CD4 construct (A66/R5NT cells). Two clones, termed Dbl cl-1 and Quad cl-4, 
were isolated. Of the gp120 and gp41 changes that were acquired by both Envs, five 
gp41 point mutations were shown to be sufficient to confer the N-terminus only 
phenotype. In Chapter Three, we determined the effect of these gp41 changes on 
antigenicity, fusion kinetics, heat sensitivity, and sensitivity to CCR5 antagonists. In our 
attempt to define the mechanism for this phenotype, recent structural data suggested 
that the gp41 mutations impact the “structural integrity” of key domains that form upon 
CD4 binding and that a sub-threshold triggering event (i.e. N-terminus only usage) is 
sufficient for the release of gp41. Surprisingly, the N-terminus only viruses that were 
derived contained defective vpu genes, which was shown to enhance infection in the 
A66/R5NT cell line. Chapter Four describes our findings that implicate the host-
restriction factor, tetherin, in mediating a spreading infection in A66/R5NT cells.  
 
PATHWAYS TO STUDYING CORECEPTOR ENGAGEMENT 
The crown of the V3 loop is the major domain that interacts with coreceptor ECLs, while 
the base of V3 along with the BS engage the coreceptor N-terminus [65]. We assessed 
the contribution of the BS/NT interaction to coreceptor engagement by developing 
replication-competent V3-truncated variants of HIV-1 R3A.  
 
The role of the V3 loop  
We previously developed a variant of dual-tropic HIV-1/R3A containing a 15 amino acid 
deletion in V3 to examine the role of V3 in coreceptor engagement  [129] (Figure 5-1). 
Because the V3/ECL interaction is important for X4 tropism, the V3 truncation led to the 
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loss of CXCR4 usage, but CCR5 use was retained. Therefore, this was a unique 
opportunity to study the determinants of coreceptor switching. To do this, the swarm was 
further adapted to regain CXCR4 usage in SupT1 cells [183]. One Env clone, termed 
∆V3-X4, maintained the V3 truncation and displayed resistance to an CXCR4 coreceptor 
antagonist by increasing dependency on the N-terminus of CXCR4. The virus exhibited 
restricted tropism in cell lines (data not shown), and was adapted to replicate in the 
CD4+ CXCR4+ CEM human T cell line to broaden its tropism [2]. An Env clone 
designated, CEM-c11, contained a severely truncated V3 with only the first 8 and last 6 
residues remaining. The severely truncated V3 was hypothesized to improve interactions 
with the CXCR4 N-terminus, however there were many other changes in Env that could 
have played a role.   
 
Dissociating HIV-coreceptor interactions 
By studying viruses that utilize certain coreceptor domains over others, we can draw 
conclusions about Env and coreceptor determinants from these particular interactions in 
isolation and the requirements for triggering gp41-mediated fusion. Mutations that 
contribute to CCR5 usage in the absence of the CCR5 N-terminal domain have been 
well-documented by Kabat [152, 176–178]. Removing the N-terminus of CCR5 and 
adapting JRCSF to utilize this CCR5∆18 mutant coreceptor drives changes in gp120, 
particularly in V3. In a complementary manner, we designed CCR5 and CXCR4 
coreceptor constructs that express the N-terminal 19 and 27 amino acids, respectively, 
fused to a CD4-based anchoring protein (R5-NT/CD4 and X4-NT/CD4). We adapted 
CEM-c11 for growth in CD4 cells that expressed the X4-NT/CD4 construct and an Env 
clone, designated CEMAX-c7, was isolated [2]. We observed newly acquired changes 
that were exclusively located in gp41, coupled with a severely truncated V3. Two 
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adaptive mutations were in the FP, one in HR2, and three others in the transmembrane 
regions and cytoplasmic tail, raising the possibility that the changes in gp41 were 
sufficient for the N-terminus only phenotype. There was a concern that a truncated V3 
loop could have caused major alterations in the CEMAX trimer structure. Therefore, a 
combination of four key gp41 mutations (A512V, F519I, G524V, and I646L) was 
introduced to R3A viruses with intact V3 loops. These changes were shown to be 
important for replication in A66/R5NT cells. We derived two mutants, designated Dbl cl-1 
and Quad cl-4, that exhibited the N-terminus only phenotype and maintained the 
previously introduced changes in gp41. Sequence analysis of both env clones revealed 
that both viruses used common mutational pathways in gp41 to acquire CCR5 N-
terminus only usage (Table 5-1). Dbl cl-1 acquired a valine at position 512, whereas 
Quad cl-4 evolved an isoleucine at this site. The F519I was maintained in both Envs, but 
Dbl cl-1 evolved an isoleucine at position 524. Quad cl-4 maintained the Val524 change. 
Ala541 is located within a stretch of residues associated with a structural domain 
responsible for restraining the gp120 C1 and C5 regions. A threonine was acquired by 
Dbl cl-1 and Quad cl-4 at this site. It is worth noting that the ∆V3-X4 R3A variant also 
acquired the A541T mutation [183]. Dbl cl-1 acquired an aspartic acid at position 640, 
while Quad cl-4 maintained the I646L change in HR2. The gain in hydrophobicity within 
the already hydrophobic FP hinted at a possible alteration in the mechanism of 
triggering. Four mutations (4x virus), excluding the change in HR2, were sufficient for 
replication in A66/R5NT cells, but five changes (5x virus) markedly enhanced replication 
kinetics. We investigated whether this gain of function could be extended to other HIV-1s 
in cell-cell fusion assays, including clade B YU2 and clade A BG505. We observed that 
both Envs could also fuse with CCR5 N-terminus efficiently when the three FP and one 
HR1-flanking mutations were introduced in wildtype Env.  
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The fusion peptide: a conserved domain of fusion machinery 
The N-terminus of HIV-1 gp41 contains the FP. This 15-20 amino acid-long segment is 
highly hydrophobic. It is thought that the structural plasticity of this domain is important 
for its function [243]. Many studies performed in the 1980s and 90s described the effects 
of mutagenizing the FP region (reviewed in [241, 242]). The FP has a number of 
glycines and alanine residues that promote the formation of an alpha-helix. However, the 
most likely structure is that of a sided alpha-helix, because these residues reside on one 
face of the structure, while other residues containing branched and bulky hydrophobic 
side chains constitute the opposite face of the helix [55, 242]. The FLGFLG sequence of 
the FP is conserved among HIV-1 strains and is homologous to SIV FPs. The N-
terminus only mutations occur in residues that are mostly conserved between HIV-1 and 
SIV strains (Figure 5-2, Table 5-2) [12, 26, 55]. Delahunty et al. showed that the glycine 
and residues contained within the FLGFLG sequence are crucial for fusogenic activity 
because substituting each glycine for a valine resulted in the inhibition of syncytium 
formation [55]. In contrast, studies of the F protein of the paramyxovirus simian virus 5 
demonstrated that mutating glycines to alanines within the FP increased fusogenicity, 
possibly stabilizing the formation of an alpha-helical [97, 200]. Similarly, substituting the 
glycine residue for an alanine in the FLGFLA sequence of an SIV FP enhanced 
syncytium formation [26]. The adaptive mutations that were maintained or acquired in 
the Dbl cl-1 and Quad cl-4 FPs contained bulky hydrophobic side chains, increasing the 
overall hydrophobicity of this region. In all cases, there is likely selective pressure to 
maintain the right balance of hydrophobicity and structure, and in some cases increasing 
hydrophobicity may enhance fusogenic activity. Recent cryo-EM and x-ray models of the 
pre-fusion trimer show the partially disordered FP pulling away from the trimer core and 
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projecting toward the solvent [136, 169]. As a result, the Ala512 and Phe519 do not 
make strong contacts with other gp120 and gp41 residues. Upon CD4 binding, a cryo-
EM map shows the FP becoming buried within a large hydrophobic pocket in the trimer 
core that includes Ile491, Ala205, and Thr244 of gp120. The phenylalanine at position 
519 is embedded in this pocket, while Ala512 is close to the fusion peptide proximal 
region and the C-terminus of HR1. Additionally, Gly524 packs against Ala662 in the 
membrane proximal region of gp41 [167]. Interestingly, the ∆V3-X4 Env acquired a 
serine at position 662, disrupting the interaction with Gly524 [183]. It is intriguing to 
hypothesize that mutating position 524 to a valine is functionally equivalent to mutating 
Ala662, and that the A662S change in ∆V3-X4 Env could have contributed to its 
increased dependency on the BS/NT interaction.  
 
FUNCTION OF CCR5 N-TERMINUS ONLY USING ENVS  
In the third chapter, I characterize 1) the effects of these mutations on structure, as 
determined by their sensitivity to a panel of anti-HIV Env monoclonal antibodies to 
conserved epitopes; 2) the sensitivity to entry inhibitors; and 3) the effects of heat on 
functional stability. The goals of these approaches were to gain insight into 
structure/function alterations and possible mechanisms. Chapter 4 explores the role of 
Vpu and tetherin within the context of N-terminus only usage.  
 
Neutralization and heat sensitivity  
Sodroski studied CD4-independent variants that are globally sensitive to neutralization 
by multiple antibodies [92, 162]. The association between the mechanism of CD4-
independence and the sensitivity to neutralization was investigated. The enhanced 
ability to transition to lower energy states upon receptor binding, or the “intrinsic 
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reactivity”, was described to modulate antibody-mediated neutralization and the 
mechanism of CD4-independence. Increased exposure of the coreceptor binding site 
that is normally formed after CD4 binding helped to explain the neutralization sensitivity. 
These features of CD4-independent Envs promote 6HB bundle formation after 
coreceptor engagement. Although a chemokine receptor-independent HIV-1 has not 
been described, the gp41 changes in N-terminus only Envs may facilitate the transition 
to overcome the final barrier to release of gp41. For this to be the case, the impact of 
these changes on antigenicity could have a generalized effect on neutralization. 
Surprisingly, gp120 epitopes of parental and mutant Envs (Quad cl-4 and 5x), including 
the CD4 binding site and N332 supersite, remained equally sensitive to antibodies, 
indicating that these changes did not have global effects on Env. There are several 
newly described gp120/gp41 interface broadly neutralizing antibodies that we also tested 
[22, 75, 101, 126]. Our results show that the mutant Envs were less sensitive compared 
to parental R3A, likely because the footprints of PGT151, ACS202, and VRC34 
antibodies include the FP. All Envs remained equally sensitive to the 35O22 antibody, 
which binds a non-overlapping epitope at the interface. Although there were no global 
effects on trimer antigenicity, our studies show that these mutations are associated with 
a 3-fold increase in neutralization sensitivity by sCD4. We also tested whether these 
Envs displayed the tendency to unfold more rapidly within specific temperature ranges, 
but did not find N-terminus only viruses to be more heat labile compared to parental 
R3A.  
 
Taken together, these data show that the antibodies tested do not recognize epitopes of 
conformational states that could account for the N-terminus only mechanism. Sensitivity 
to heat was also retained, therefore these mutations do not create Envs with reduced 
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functional stability. In this context, receptor binding is unquestionably required, though 
coreceptor engagement is altered. Because massive global changes of Env could not 
help to explain the mechanism of the phenotype, we hypothesize that the “internal 
wiring” must be affected instead, consistent with the model of energetic requirements of 
entry that was proposed by Sodroski [92, 162]. An energy barrier associated with CD4 
binding is described, and we propose that a similar barrier for coreceptor engagement 
must be overcome to transition to the lowest energy state. As Kabat had suggested for 
HIV variants containing gp120 mutations that confer use of a coreceptor lacking the N-
terminal domain [152, 177, 178], our N-terminus only Envs containing gp41 mutations 
may also effectively lower the energy threshold for the release of the FP for fusion 
(Figure 5-3). But how do changes in gp41 impact structure of the Env trimer, gp41 
release, and fusion?  What cooperative interactions within the trimer are relevant to this 
effect? Understanding this possible sub-threshold level of triggering may give us clues 
about structure, where mutations could impact the relationship between coreceptor 
engagement and the release of gp41. These questions will be further explored in this 
chapter with possible experimental approaches.  
 
Sensitivity to gp41 fusion inhibitors 
We also investigated the effect of these gp41 mutations on viral sensitivities to gp41 
inhibitors. The N- and C-termini of gp41 become transiently susceptible to inhibitors 
within a kinetic window between CD4 binding and 6HB formation. Both regions are not 
exposed symmetrically as fusion progresses. The exposure of HR1 is dependent on 
chemokine receptor binding, and C37 inhibitor is an HR2-based peptide that targets the 
HR1 domain and prevents the formation of the 6HB [35, 113]. Conditions that alter the 
rate of fusion have been shown to influence the inhibitory potency of C-peptides [188]. 
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We showed that 5x and Quad cl-4 exhibited less sensitivity and higher IC50 values 
compared to R3A during infection of U87.CD4.CCR5 cells. We hypothesized that Quad 
cl-4 and 5x displayed faster fusion kinetics because because coreceptor engagement is 
reduced to just the BS/NT interaction and there is only a minimal requirement to trigger 
gp41. Therefore, there is a shorter kinetic window in which C37 can interact with the 
HR1 binding site. For 5-Helix, which targets the gp41 C-terminal region of a short-lived 
intermediate state, inhibition is rapid and irreversible [113]. Therefore, it is perhaps 
unsurprising that parental and N-terminus only pseudoviruses were equally sensitive to 
this kinetically restricted inhibitor.  
 
A model for tetherin-mediated enhancement of N-terminus only usage 
In selecting for viruses that exhibited the ability to replicate exclusively using the 
coreceptor N-terminus, we consistently observed the loss of Vpu. In Chapter 4, we 
explored the role of Vpu and tetherin in this context. Vpu antagonizes tetherin by 
targeting it for proteosomal degradation. We demonstrated that the loss of Vpu conferred 
a growth advantage to N-terminus only viruses in T cell lines. Remarkably, we found that 
this phenotype was, in part, promoted by tetherin. CRISPR/Cas9 technology was used 
to ablate tetherin expression in T cells. We observed delayed infection of A66/R5NT 
tetherin-null cells by N-terminus only viruses. Tetherin is usually viewed as a restriction 
factor, but in this case it promotes transmission in cell culture. We hypothesize that the 
accumulation of large cell-free aggregates or cell-associated virions may work en masse 
to engage CD4 and a severely compromised coreceptor. The introduction of a stop 
codon in vpu releases tetherin to mediate cell-to-cell spread as an unintended 
consequence of being unopposed. There is in vivo and in vitro evidence that Vpu-
deficient HIV-1 can overcome tetherin-mediated restriction in the context of cell-to-cell 
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transmission [9, 90, 107, 108, 122, 209, 222]. Some Vpu-deficient strains can evolve in 
in vivo compartments [9, 88, 107, 175, 208]. In this context, the loss of Vpu may be 
selected for in vivo to compensate for sub-optimal entry conditions.  
 
FUTURE DIRECTIONS FOR N-TERMINUS ONLY USING VARIANTS 
Future studies should continue to define the molecular determinants of N-terminus only 
usage. Recent structural insights should also be used to guide mutagenesis of Env at 
interfaces thought to be involved in post-receptor binding events.  
 
The role of tetherin in N-terminus only usage 
To further investigate the hypothesis raised in Chapter 4 that tetherin mediates 
enhancement of N-terminus only usage, SupT1-derived cells treated with CRISPR-cas9 
technology can be used. Electron microscopy imaging can first be used as a qualitative 
method to visualize these T-cell lines with or without nascent cell-associated, tethered 
Vpu-deficient virions. To examine the efficiency of cell-to-cell spread of HIV-1 between T 
cells in the presence or absence of Vpu (and antagonized or unantagonized by tetherin), 
a flow cytometry assay can be performed to quantify the appearance of Gag+ target cells 
after coculture with infected cells. Gag transfer from cells infected by wildtype or Vpu-
deficient virus to dye-labeled target cells can be followed over a period of 24 hours, a 
time frame in which dissemination is by direct cell-to-cell rather than cell-free transfer 
[39, 108, 110, 149, 189, 219]. We expect that the presence of unantagonized tetherin 
mediates faster transmission kinetics of cell-to-cell dissemination in the context of N-
terminus only usage.  
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Sensitivity to coreceptor antagonists 
In addition to studying gp41 fusion inhibitors, we also investigated the sensitivity of N-
terminus only Envs to coreceptor antagonists in chapter three. Maraviroc is a small 
molecule that prevents HIV entry by locking the CCR5 ECLs in an inactive conformation 
that is no longer recognized by HIV-1 [117]. Surprisingly, we found that Envs that were 
adapted for replication on the N-terminus were equally sensitive to Maraviroc compared 
with parental R3A. There are a few ways that this striking finding could be interpreted. 
Steric hindrance is insufficient to account for their mechanism of action [117]. Because 
the N-terminus forms a disulfide bond with ECL3, the conformation of the N-terminus 
may be equally affected by inhibitor binding. In this scenario, N-terminus only viruses are 
no longer able to recognize the N-terminus or the ECLs. Alternatively, N-terminus only 
viruses may still be capable of using the ECLs if available, but can engage the N-
terminus in the absence of ECLs in U87.CD4.R5NT cells. In this case, the CCR5 ECLs 
would be unavailable for use when CCR5 is inhibitor-bound, resulting in coreceptor 
antagonist sensitivity. A third possibility suggests that even though coreceptor 
antagonists may bind to a common target, inhibitor-bound receptor conformations 
cannot be assumed to be equal; different allosteric modulators may produce different 
conformations of the receptor [236]. Maeda et al. showed that Sch-C, TAK-779, and a 
small molecule compound called 873140, produced different CCR5 antibody binding 
profiles [145]. Therefore, perhaps TAK-779 and Maraviroc produce similar conformations 
of CCR5 that block N-terminus only viruses. In contrast, other allosteric modulators skew 
the conformational profile and display different affinities for gp120. Given this, then it is 
possible that N-terminus only viruses would exhibit resistance by exclusively utilizing the 
free N-terminal domain. As an interesting corollary to this hypothesis, heterologous HIV-
1s, such as YU2 or BG505 N-terminus only Envs, could be employed to test whether 
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inhibitor sensitivity is isolate-dependent. To test whether the N-terminus is indeed 
structurally modified, FACS with N-terminal targeting antibodies could be performed 
under saturating conditions of inhibitor. To test whether the sensitivity to antagonists is a 
universal characteristic of N-terminus only Envs, other compounds, like AD101 or Sch-C, 
could be employed. If there is a differential sensitivity profile between these compounds, 
then these compounds likely act in disparate patterns [117, 236], which has implications 
for clinically resistant Envs that may have increased dependency on the N-terminus 
[193].  
 
HIV-1 coreceptor switching: common determinants between the N-termini? 
There are several GPCRs expressed on the surface of human CD4 cells, but HIV 
typically interacts with only CCR5 and CXCR4 in vivo. V3 is the key determinant for 
coreceptor switching from CCR5 to CXCR4. As few as one amino acid change in V3 can 
be sufficient to confer CXCR4 use [214, 216]. The Dbl cl-1 R5 N-terminus only virus 
retained X4 tropism, but was unable to utilize the CXCR4 N-terminus in the absence of 
ECLs, suggesting different determinants in CCR5 and CXCR4 N-terminus only usage. 
Although not fully characterized, we adapted Dbl cl-1 to acquire the ability to use both 
CCR5 and CXCR4 N-termini in the absence of ECLs. These findings suggest that 
common structures shared by these coreceptor regions could be recognized by these 
dual-N-terminus only (“dual-NTO”) viruses. Moreover, these variants provide an 
opportunity for future studies on determining the structural commonalities of CCR5 and 
CXCR4 that HIV-1 recognizes to shift coreceptor usage. Clones that efficiently mediate 
dual N-terminus only represent useful tools to analyze structural features common to 
both N-termini and to develop therapeutics that target the BS/NT interaction. CEMAX 
was utilized to study the biological activity of tyrosine-sulfated mimetics [2]. The new 
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generation of N-terminus only Envs with intact V3 loops may serve as valuable reagents 
within small molecule drug screens that target the interaction of Env with the N-terminus.      
 
Structure-guided mutagenesis of wildtype HIV-1 Env 
The recently emerging structures of Env prompted questions about where the five gp41 
mutations are located in the context of the trimer. Do these mutations interact with 
gp120? Do they occupy key sites affected by conformational changes after receptor 
binding? In the pre-fusion ground state, the FP projects outward into the solvent. This 
finding was also observed in several x-ray structures of the ground state [91, 127, 136, 
169, 220]. Hydrogen/Deuterium Exchange coupled with Mass Spectrometry (HDX-MS) 
has also been used to probe the conformational dynamics of the trimer. Unstructured or 
flexible regions typically undergo rapid deuterium exchange, whereas stable hydrogen 
bonding networks or highly occluded domains react less readily. Guttman et al. reported 
that a moderate level of exchange protection was shown for the FPPR, in contrast to the 
FP that was fully exchanged within seconds, suggesting that the FP was solvent-
exposed [91]. This is surprising because the highly hydrophobic FP is anticipated to be 
sequestered in the pre-fusion state. However, in Env SOSIP trimers, the FP may be only 
loosely buried and other domains that are missing, such as the membrane proximal 
external region, in these truncated soluble constructs could participate in protecting the 
FP.   
 
Upon CD4 binding, cryoEM data showed the induction of previously unknown 
rearrangements in gp41, including a change in trimeric HR1 that causes the N-terminal 
portion of HR1 (HR1N) to move away from the core. The gp120 C1 and C5 regions 
translocate in the same manner to avoid clashing with HR2, while the fusion peptide 
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proximal region (FPPR) and HR1N form a stable helix that packs against the C-terminus 
of HR1 and HR2 of a neighboring protomer. These rearrangements created a larger 
cavity near the trimer core for the FP to occupy [167]. The effects of CD4 binding was 
also monitored by HDX-MS [91]. Within gp41, the FP was shown to become fully 
protected, in contrast to the FPPR. A complex network of specific interactions with 
conserved gp41 and gp120 residues likely stabilizes the CD4-bound intermediate. A 
comparison of the effects of CD4 binding suggests that two allosteric networks are 
triggered: The first involves gp120 rearrangements that ultimately unmask the co-
receptor binding site and prime gp120 for CCR5 engagement, and the second links CD4 
binding to the formation of elements that are poised for membrane fusion following 
coreceptor engagement.  
 
Four of the N-terminus only gp41 mutations appear to be located in key packing areas 
that form upon CD4 binding and that are in place to trigger the release of the FP ([167] 
and A. Ward, personal communication). The phenylalanine at position 519 interacts with 
Ile491, Ala205, and Thr244 of gp120, while Ala512 packs against Arg588 of HR1. 
Additionally, Gly524 interacts with Ala662 in the membrane proximal region of gp41. 
Ala541 is located in the middle of the stable FPPR/HR1N helical region that interacts with 
Leu592 and Ile/Leu595 at the C-terminal end of the neighboring HR1. Given these 
findings, we hypothesize that each mutation creates instability in these packing areas 
that are insufficient, but poised, to liberate the fusion peptide at a sub-threshold level of 
triggering following the minimal interaction with the CCR5 N-terminus (Figure 5-3).  
 
N-terminus only Envs can be useful tools to understand biological functions of receptor-
induced conformational states and may reveal testable hypotheses regarding how the 
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gp41 FP is released and the structural constraints that are on this domain. In order to 
further examine the mechanism of N-terminus only usage, the kinetic determinants of 
gp41 inhibitor sensitivity, and the requirements for the gp41 pre-hairpin intermediate 
formation as modeled in Figure 5-3, time-of-addition experiments could be performed 
with U87-derived cells. The T20 peptide binds to intermediate conformations of gp41. In 
these experiments, a panel of viruses is preincubated with U87.CD4.R5NT cells (and 
U87.CD4.CCR5 cells as a control) at 4°C to promote surface attachment (unbound virus 
is washed away) and then shifted to 37°C to initiate fusion. Fusion inhibitors, such as 
T20 or C37, can then be added at different time points to determine whether inhibitor-
susceptible conformational intermediates have long or short lifetimes. Additionally, a 
soluble CCR5 N-terminus-based peptide can be used to reconstitute the R5-NT/CD4 
chimeric coreceptor and trigger the release of gp41 when added to U87.CD4 cells. In 
this experiment, gp41 inhibitor can be added before, during, and after the addition of the 
triggering peptide at different time points. These experiments concerning mechanism will 
reveal if exposure to only the coreceptor’s N-terminus shortens the lifetime of the 
inhibitor-susceptible fusion complex intermediate, leading to 1) a rapid resolution of the 
pre-hairpin state, 2) inefficient inactivation of Env, and 3) large increases in IC50s. If this 
is the case, then this mechanism can help to explain the model of the lowered energy 
threshold for gp41 triggering as illustrated in Figure 5-3.  
 
Questions about the structural consequences of gp41 mutations that confer N-terminus 
only usage can now be addressed using this CD4-bound CryoEM map to guide the 
introduction of reciprocal mutations that may induce the same N-terminus only 
phenotype. Gp120 and gp41 mutants can be evaluated in pseudotype assays with U87 
cells stably expressing CD4 and the R5-NT/CD4 construct. As a starting point, reciprocal 
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mutations of the five N-terminus only mutations can be investigated. Replacing the 
Val512 with wildtype alanine in 5x env will establish a baseline from which the 
Arg/Lys588 reciprocal mutation in HR1 can be studied. Introducing an aspartic acid 
residue at this site may disrupt the interaction with the N-terminal residue of gp41. Ile491 
and Thr244 residues make hydrophobic interactions in the ground state, but Ala205 only 
makes contact with the Phe519 or the Ile519 mutation in the CD4-bound state. 
Therefore, Ala205 is the most appropriate contact residue to study. Reverting the Ile519 
back to phenylalanine creates an appropriate background for introducing a polar residue, 
such as arginine, at position 205. Ala541 located in the FPPR/HR1N, interacts with 
Leu592 of HR1 of a neighboring protomer. The leucine at position 592 can be mutated to 
glutamic acid to disrupt the interaction with Ala541. It is unlikely that I646L in HR2 has 
an effect on destabilizing the CD4-intermediate from a structural perspective, but the 
interaction between Gly524 and Ala662 can be disrupted by the addition of a bulkier 
aliphatic residue, such as an isoleucine in place of the Ala662. The cryoEM map of the 
CD4-bound structure can be used to also introduce mutations in particular positions 
within gp120 and gp41 domains that orchestrate the conformational rearrangements that 
occur after coreceptor binding.  
 
The series of x-ray and cryoEM trimer structures have provided snapshots of the pre-
fusion and CD4-bound intermediate states, revealing substantial conformational 
changes that must occur in gp120 and gp41. By assessing whether these structure-
guided mutations recapitulate the N-terminus only gain of function, we can build a 
comprehensive functional model for the molecular rearrangements that occur in gp120 
and gp41 to prime Env for membrane fusion.  
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CONCLUDING REMARKS 
The primary goal of this thesis was to advance our knowledge of coreceptor 
engagement by isolating the BS/N-terminus interaction and deriving novel HIV-1 
envelopes capable of fusion and replication on the CCR5 N-terminus in the absence of 
ECLs. Despite detailed knowledge of the BS/NT and V3/ECL interactions and the 
process of membrane fusion, the requirements for the formation of conformational 
changes after coreceptor binding are not fully described. This thesis brings together 
complementary work by Kabat and Ward to expand our knowledge of the structural and 
functional consequences of dissociating the coreceptor engagement process and how 
gp120 and gp41 changes affect coreceptor interactions and the formation of stable 
conformational states that are poised to induce membrane fusion.  
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FIGURES 
 
 
Figure 5-1: Scheme summarizing the derivation of CEMAX virus. in vitro adaptation 
steps are shown with published studies of each adaptation indicated on the side. Each 
adapted virus was serially passaged in a 1:10 mix of permissive and non-permissive 
cells, respectively, until infection of greater than 10% of cells (by immunofluorescence 
microscopy) occurred. Virus was then serially passaged in target cells only.   
 
 
R3A
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ΔV3-X4
CEM-c11
CEMAX-c7
Meissner et al. Virology, 2004.
Laakso et al. PLoS Path, 2007.
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Acharya et al. ACS Chem Bio, 2011.
Acharya et al. ACS Chem Bio, 2011.
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Figure 5-2: Fusion peptide and HR1 proximal region amino acid frequency of HIV-1 
and SIV. HIV-1 and SIV pie charts are shown on the top and bottom sections, 
respectively. The HxB2 reference sequence is shown above the HIV-1 pie charts (all 
clades were included for HIV). A consensus sequence is shown above the SIV pie 
charts. Positions 512, 519, 524, and 541 are highlighted in red in both sequences. 
Mutations at these sites are responsible for conferring the N-terminus only phenotype. 
Data were gathered and analyzed using the Los Alamos National Laboratory website’s 
AnalyzeAlign tool (current as of 9.18.16).  
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Virus Sequence
HIV-1
NL4-3 AVGIGALFLGFLGAAGSTMGAASMTLTVQAR
R3A AVGIGAVFLGFLGAAGSTMGAASMTLTVQAR
YU2 AVGLGALFLGFLGAAGSTMGAASITLTVQAR
BG505 AVGIGAVFLGFLGAAGSTMGAASMTLTVQAR
Dbl cl-1 VVGIGAVILGFLIAAGSTMGAASMTLTVQTR
Quad cl-4 IVGIGAVILGFLVAAGSTMGAASMTLTVQTR
SIV
mac239 GVFVLGFLGFLATAGSAMGAASLTLTAQSR
mac251 GVFVLGFLGGLATAGSAMGAASLTLTAQSR
smE660 GVFVLGFLGFLATAGSAMGAASLTLSAQSR
TABLE 5-2. Alignment of HIV-1 and SIV gp41 N-terminal regions
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Figure 5-3. Model for energy barriers during the events of HIV-1 entry. Typical CD4 
and CCR5 binding energy barriers are shown (left). N-terminus only usage suggests a 
lower energy barrier for CCR5 engagement (red) as indicated by a smaller energy hump 
(left).   
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